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Su, Zhenbi (Mechanical Engineering)
NUMERICAL EVALUATING PULMONARY HEMODYNAMICS AND RV AFTERLOAD
IN PULMONARY ARTERIAL HYPERTENSION PROGRESSION
Thesis directed by Profs. Robin Shandas and Kendall S. Hunter
Pulmonary arterial hypertension (PAH) is an important determinant of morbidity and
mortality in children with congenital heart disease. Previous and current investigations
on pulmonary vascular stiness (PVS), input impedance and right ventricular (RV) power
have found PVS to be an important contributor to ow energy power, and thus, afterload.
However these investigations focus on the analysis of clinical data, which requires long term
observation and inspection of a great number of individuals, whose clinical pathogenesis may
not be the same. It is dicult if not impossible to vary stiness/resistance in an example
system within clinical or animal studies, and it is dicult to separate the contributing eects
of stiness and ow from clinical results.
Here we proposed numerical artery models based on the clinically and experimentally
measured parameters for children and calves, to determine if they could oer clinically rele-
vant hemodynamic information on the circulation. With non-specic on pulmonary vascular
structure information, we can create a realistic computational simulation environment, which
can be used to test our theories regarding various associations between hemodynamic and
mechanical variables in the human or animal pulmonary vasculature. These models could be
useful in helping evaluate the ecacy of newly designed therapies that may target particular
components of RV afterload such as proximal vascular stiness or distal vasoconstriction,
and as a tool to examine disease progression, and others.
Through these types of studies, we will obtain a better understanding of how structural
adaptations that occur in pulmonary vascular disease aect hemodynamics, vascular function
and subsequently impedance and right ventricular (RV) afterload. Several achievements are
iv
obtained: 1) eect of these experimental measurable parameters on hemodynamics when
PAH progresses to worsen; 2) hemodynamics play an important role in progressing PAH; 3)
provide possible prediction of WSS, impedance, RV power and pulsatility of hemodynamics
based on easily obtained measurable parameters; 4) decreasing or reversing proximal vascular
remodeling can provide treatment of PAH as well as decrease mean pressures (mPAP).
Overall, these results suggest a close association between PVS, PVR and hemodynamics,
that hemodynamics may play an important role in progressing PAH, and that treatments
should target decreasing or reversing upstream vascular remodeling in addition to decreasing
mean pressures.
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Chapter 1
Introduction
1.1 Background
Pulmonary arterial hypertension (PAH) is a relatively uncommon but frequently fatal
disease in children and adults, especially for women. It is dened as a pulmonary arterial
pressure >25 mm Hg at rest or >30 mm Hg after exercise, although clinically patients are
often asymptomatic until their pulmonary artery pressure exceeds 60 mm Hg. In 2007, the
World Health Organization (WHO) created the following three subgroups for PAH [2]:
I. Idiopathic PAH. Cause of PAH is unknown. Patients have no limitation of physical
activity.
II. Familial PAH. Disease is inherited. Patients have slight limitation of physical
activity.
III. Associated with PAH. Disease is caused by other conditions or toxins. Patients
have markable limitation of physical activity.
PAH was rstly described and researched clinically over 100 years ago by Romberg [3].
The rst observe of relation between PAH and congenital heart disease was examined by
Eisenmenger [4] and `Eisenmenger syndrome' was named which reects pulmonary hyper-
tension in patients with large left to right cardiac shunts [5]. In 1958, Heath and Edwards
proposed a grading system for pulmonary hypertension based on the severity of vascular
changes observed in 67 children with congenital heart disease and one case of idiopathic
pulmonary hypertension [6]. This classication scheme that shows a stepwise progression of
2disease from pulmonary hypertension I to grade VI, was initially introduced to examine the
potential reversibility of hypertension associated with congenital heart defects. However this
system remains unclear whether such a progression occurs and whether it reects severity or
duration of pulmonary hypertension so its application needs more inspection and verication
[7]. Since 1980, the amount of patients with PAH have increased, particularly among women
and older adults [8].
PAH is a serious condition clinically involving biology, mechanics and hemodynamics
for which there are treatments, but unfortunately no cure currently. Current treatments
with medicine on patients could improve numerous patients with normal lives, however,
complications in PAH limit our understanding and nding out the pathologies of PAH.
1.2 Literature Review
1.2.1 Clinical and Experimental Research on PAH
Clinical and experimental methods are the most direct approaches to investigate PAH
and they have been performed through the whole PAH research, from the beginning to
current and future. These clinical and experimental investigation for PAH involve a series
of functions. Through these functions we diagnose and conrm PAH presence, identify and
analyze the disease cause/pathologies, determine the prognosis and nd out the appropriate
medicine/therapy. The diagnosis of pulmonary hypertension is divided into two stages,
detection and characterization [1]. Through the detection process the cause of symptoms
and the presence of PAH are determined and detected. In the characterization process
the specic clinical context of the PAH is determined. Figure 1.1 shows the guidelines for
evaluating pulmonary hypertension [1]. At the initial condition, three symptom acquirement
methods, symptom evaluation, screening and incidental nding were performed before the
detection is launched. There are many detection assessments for pulmonary hypertension
which include the physical examination, chest X-ray, electrocardiogram (ECG), and Doppler
3echocardiogram. Here physical examinations are taken to conrm the PAH which include
left parasternal lift, accentuated pulmonary component, RV, etc. Once the PAH suspect is
targeted, the characterization will be taken which include two tests, essential and contingent
tests to determine severity and prognosis accurately, and to nd out a proper treatment.
Figure 1.1: Guidelines for evaluating pulmonary hypertension [1].
Clinical and experiential research on PAH in hospitals and laboratories to individual
patients is the earliest research on the PAH, and the earliest PAH case was examined in
4100 years ago [3]. Unfortunately, the diagnosis of PAH is not made before the disease is
relatively severer. So patients with PAH have been examined with disease throughout the
pulmonary arterial tree. For example patients are often asymptomatic until their pulmonary
artery pressure exceeds 60 mm Hg. PAH is complicated which may be associated with a
variety of comorbid conditions, symptomatic evidence of related illnesses should be consid-
ered. Developing accurate methods and techniques to detect and diagnose the disease when
it is still asymptomatic is the most important task in PAH research. These methods and
techniques are targeted to several symptoms which are relatively sensitive to PAH, such as
oxygen saturation, cardiac output, and pulmonary vascular remodeling.
In the PAH, the oxygen saturation in blood is decreased, as well as the cardiac output
from the right ventricle is decreased. Both decreased oxygen saturation and cardiac output
yield the exertional dyspnea. This symptom is very common in PAH earlier stage and was
present in 60% of patients in the National Institutes of Health (NIH) prospective study of
patients with PAH [9]. There are several symptoms relate to change of oxygen saturation.
In blood ow, the density and viscosity are increased which increase pulmonary diastolic
pressure and restricts the blood transportation in lung, as a results orthopnea and paroxysmal
nocturnal dyspnea are yielded. Through diagnosing Raynaud phenomenon, arthralgia, or
swollen hands and other symptoms doctor and scientists nd PAH related disease at a earlier
stage, .
The pulmonary vascular remodeling is caused in PAH which plays key role in is pro-
gression. It changes the components and function of pulmonary vessels and RV functions,
which include cardiac output, pulmonary pressure, ow rate and stiness, even geometry.
Based on dierences in ow rate/waveform, pressure, vascular distensibility between the
PAH state and the normal condition, several methods and devices have been introduced to
measure and monitor these changing, then diagnose symptoms of the PAH. However these
investigations focus on the analysis of clinical data, which requires long term observation
and inspection for a great number of individuals, whose clinical pathogenesis may not be the
5same. It is dicult for clinical data to vary mechanical or physical parameters in an example
system, and clinical results can not elucidate relationships between mechanical or physical
reasons and PAH.
1.2.2 Theoretical and Basic Research on PAH
To investigate PAH more comprehensively, several techniques and tools beyond clin-
ical and experimental methods were employed, which include mathematical models and
numerical simulations. The earliest studies are to analyze simplied models, which include
simplied geometries, arterial dimensions and boundary conditions. The Windkessel model
is a simplied model which employs the cardiovascular system with a compliant section and
a resistive section. This model considers the compliant artery as a capacitor to store blood
during systole, while the elastic artery discharges the stored blood through the resistive
branches of the smaller arteries during diastole [10]. The pressure and ow waveforms cal-
culated by this model are quite close to those clinically and experimentally measured in the
pulmonary arteries. There have been several types of Windkessel models in PAH research
and more realistic models are developed with many elements in order to rene the waveform
predictions [11]. Besides Windkessel models, tube model is another simplest model which
was developed earlier to represent the artery and dierent conditions including tube mate-
rials, mechanics and uid properties inside the tube were applied [12, 13, 14]. Anliker et al.
[15] developed a mathematical model based on the pure resistance condition to analyze the
pulses probation in the artery. Stettler [16] improved the mathematical model to the more
realistic bifurcation and stenoses, based on the earlier theoretical studies. These simplest
models are employing mathematic models with dierent boundaries and properties setting
to simulate the pressure and waveform in pulmonary circulation. Although they provide
relatively useful information to predict the hemodynamics of PAH, the accuracy of such
models is limited because the velocity and pressure distribution over the cross section of the
tube are ignored. Based on these models, more models have been developed which show
6more realistic pulmonary circulation. A model of the human arterial system was constructed
based on the anatomical branching structure of the arterial tree by Avolio [17]. Vascular
impedance, pressure and ow waveforms were examined at various locations in the system
and good agreement was reached with experimental measurements. Chadwick [18] developed
an arterial model presenting the pulse-wave propagation in it while blood ows into small
side branches. This model and study can be considered as the ow propagation from the
main branch to small branch. All these studies employed mathematical model to calculate
the ow and pressure propagations in simplied arteries, which aected by the supplications
of the arterial geometries, material mechanics, uid properties and boundary conditions.
In recent years, computer aided tools were used to investigate PAH and more realistic,
patient-specic three dimensional models have been developed based on these tools. Model-
ing of cardiovascular biomechanics and hemodynamics from patient-specic data is based on
the accuracy imaging acquired from clinical and experimental measurements and becomes
more and more popular in recent decade. Several methodologies utilizing Computed tomog-
raphy (CT), Magnetic resonance imaging (MRI) and ultrasound to regenerate the three-
dimensional anatomy of the cardiovascular system have been examined. Multi-detector row
computed tomography (MDCT) improved the CT in the temporal and spatial resolution,
which permitted substantial expansion of potential indications for CT imaging. With three-
dimensional reconstruction, MRI provides additional information about pulmonary artery
abnormalities that are dicult to evaluate with conventional cardiac imaging techniques [19].
Ultrasound technique which is low cost, safe to human body also helps us to reconstruct pul-
monary arterial model. The problem is that techniques are needed to improve to develop
three dimensional models from current two dimensional models. [20, 21].
With these anatomy reconstruction tools, a series of realistic three dimensional mod-
els have been developed. Blood ow and uid structure interaction (FSI) between blood
ow and pulmonary vascular arteries were simulated numerically, to examine the pulmonary
circulation and performance. FSI technique is among the most popular approaches in sim-
7ulating the motion and mechanics of blood and arterial mechanics in pulmonary. Because
of the exile vessels, interactions between an internal ow and wall deformation often plays
an important role in biological function or dysfunction of vessels. These interactions is
complicated and involve a serious uid and solid mechanical phenomenon.
1.2.3 Roles of Solid and Fluid Mechanics on PAH
Pulmonary circulation is the blood ow circulating in exible pulmonary vascular ar-
teries, which involves the uid mechanics and solid mechanics. In PAH, the pulmonary
pressure increase and much load is put on the blood, which increases blood density. The
increased density aects blood constituents and nally changes the viscosity. The viscosity
is increased and lows the blood transportation in pulmonary circulation. An artery has three
layers: an outer layer of tissue, a muscular middle, and an inner layer of epithelial cells. The
mechanics in the vascular vessels is complicated and several parameters are considered for
mechanics: stiness (PVS), resistance (PVR) and distensibility.
1. Relationship between PVR and PAH. PVR measurement has been the standard
diagnostic for evaluating both the signicance of PAH and the extent of vascular response
to therapies. Using only PVR to investigate the PAH however ignores the eect of PVS on
right heart afterload and disease severity. The current standard for measuring PVR is by
invasive measurement of ow and pressure in the pulmonary arteries. However, the invasive
technique limits it use in the routine followup of patients undergoing treatment for PAH.
A noninvasive method of evaluating PVR was developed to allow more frequent assessment
of PVR, facilitate the monitoring of individual patient responses, and provide remote site
assessment of PVR by Shandas et al [22]. Weinberg et al. [23] used a single pressure
measurement combined with Doppler measurement of ow in the MPA to provide a method
to quantify both pulmonary vascular compliance and PVR. Such additional information may
provide a means to further categorize patients for subsequent treatment, including surgical
correction of congenital heart defects. Since Weinberg's study, many others [24, 25, 26] have
8investigated stiening as it relates to PAH; these studies are reviewed in detail below.
2. Relationship between PVS and PAH. The pulmonary vascular remodeling involved
in PAH increases resistance to ow requiring higher upstream driving pressures to be gen-
erated by the right ventricle. Increased pressure causes distension and stiening of the
proximal pulmonary artery and might also result in vessel wall remodeling, which in itself
may inuence stiness. Thus both, pressure and changes in the vessel wall contribute to
proximal pulmonary artery stiening [27]. Increased PVS is correlated with patient mor-
tality and RV afterload [24, 25, 26]. This study is mainly using experiments methods to
investigate the mechanics of pulmonary arteries, by studying the protein in arterial wall.
Lammers [28] investigated the mechanics of artery. PAH causes an increase in the strains
associated with the physiological pressure range but had no eect on the strain of transition
from elastin-dominant to collagen-dominant behavior. Stress-strain behavior of fresh arte-
rial tissues further revealed that the diastolic strain and baseline slope of the stress-strain
curve are determined by elastin mechanics, and the strain at systole becomes increasingly
dependent on collagen mechanics as a result of hypertension. Results show that elastin is an
important passive material for carrying the load imposed on the proximal pulmonary artery
at physiological pressure ranges, and that the increase in stiness of elastin acts to maintain
the physiological strain range within the more elastin-dependent region of the stress-strain
curve.
3. Relationship between WSS and proximal distensibility. In the proximal pulmonary
arteries (main, left and right pulmonary arteries), the increased pressure in PAH causes the
pulmonary arterial distension. The media and adventitia both increase in thickness in re-
sponse to PAH, which increase the arterial diameter and thickness together. The pulmonary
artery distensibility evaluated using imaging techniques and ex-vivo methods has been ad-
dressed in order to assess pulmonary hemodynamics and diagnose pulmonary vascular disease
[29, 30, 28]. It is believed that the proximal diameter and thickness may reect the degree
of vascular remodeling, thus making it a very interesting marker for evaluation of PAH pro-
9gression. In the PAH, increased arterial diameter and thickness decrease WSS. Reduced
steady WSS could reduce distal dilation response and in turn increase proximal pressure.
Shear-induced mechanotransduction (the conversion of mechanical stresses to biochemical
responses) is particularly important in arteries, in which blood ow regulates vascular tone
and structure. Subtle changes in the ow rate and shear stress may alter cell behaviors
[31]. Interactions between shear stress and the endothelium clearly regulate important de-
velopmental, homeostatic and adaptive mechanisms in arteries. They are also an important
inuence in cardiovascular pathology [32, 33].
RV function is exquisitely sensitive to increases in afterload and PVR is believed to
well-quantify RV afterload which is generally considered as the primary determinant of mor-
tality. The RV performance markedly depends on the afterload. The RV ejection volume
has been found to relate with exercise in healthy subjects given the decreased PVR and in-
creased contractility of the RV free wall [34, 35]. In patients with PAH, the decreases in RV
ejection volume are not indicative of decreased RV contractility but mainly reect increased
afterload [36]. Hunter et al. [26] investigated the eect of PVS on the pulmonary circuit
and the total afterload, which provides the relation between the cardiac function and the
pulmonary hemodynamics. The pulmonary vascular impedance is a frequency-dependent
function encompassing information about resistive, capacitive and inertial components of
vascular hydraulic load, as well as the extent of pulse wave reection [37]. Few studies have
been performed in patients, due to a requirement for simultaneous recordings of high delity
pressure and ow signals. Results are reported as spectra of pulmonary vascular impedance
amplitude and phase versus frequency. Pulmonary vascular impedance spectra in patients
with pulmonary hypertension demonstrate increases of both the steady component (increased
resistance) and oscillatory component (elevated pulmonary arterial characteristic impedance
and increased pulse wave reection) of hydraulic load [37]. Decomposition of pressure and
ow into forward and backward components show an increased amplitude and early arrival
of the reected pressure wave, contributing to unfavorable loading of the still-ejecting RV
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[37]. A preliminary report has suggested that high characteristic impedance could predict
better than pulmonary vascular impedance the occurrence of severe RV failure after cardiac
transplantation [38]. RV power, consisting of both a mean component and an oscillatory
component, quanties the ventricular power needed to move blood through the pulmonary
vasculature [39, 40, 41]. The input impedance, PVS and PVR provide a more comprehen-
sive means of evaluating PAH and assessing vascular reactivity than that currently available
through PVR measurements alone. Previous and current investigations on the pulmonary
vascular stiness (PVS), input impedance and RV power [42, 23, 26] have found PVS to be
an important contributor to power, and thus, afterload. The symptoms of pulmonary hy-
pertension are explained by a decrease in cardiac output caused by an afterload-induced RV
failure. These previous and current investigations focus on the analysis of clinical data, which
are useful but currently lacks sucient detail to establish relationships between changes in
vascular stiness and their eects on local and global pulmonary hemodynamics.
1.2.4 Current Challenges of Fluid Structure Interaction (FSI) Study on
PAH
PAH yielded pulmonary vascular remodeling requires knowledge of uid mechanics
and solid mechanics involved in the pulmonary vascular hemodynamics. FSI is important in
coupling of these mechanics which helps researchers to understand many aspects of vascular
physiology and clinical therapy, and assists physicians identifying patients exhibiting the
development of vascular disease. Blood ow interacts both mechanically and chemically
with vessel wall, giving rise to complex FSI whose mathematical analysis is still incomplete
and which are dicult to simulate numerically in an ecient manner. At a macroscopic
level, the arterial wall is a complex multi-layer structure that deform under blood pressure.
Even constitutive equations have been proposed for the structural behavior of the vessel wall,
its elastic characteristics in-vivo are still very dicult to determine and are usually inferred
from pulse propagation data.
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The major computational challenges in pulmonary uid and structure mechanics is ac-
curate modeling of the FSI between the blood ow and arterial walls, which include the vascu-
lar geometries, the uid and solid properties, the computational boundary conditions. Solid
and uid properties, which include the blood density, viscosity, vascular density, stiness and
resistance. Accurate measurements of these properties restrict the accurate of model devel-
opments in computational simulation of pulmonary arterial hemodynamics. Much has been
accomplished in FSI modeling research since the early 1990s [43, 44, 45, 46, 47, 48, 49, 50],
and a good portion of that FSI research has been directed towards arterial uid and structure
mechanics.
The arterial geometry acquisition is mainly depended on the techniques of imaging
methodologies, which including imaging tools and measurements methods, while it aects
the results but the eects are typically local [51]. The computation boundary conditions,
inow and outow boundary conditions aect the large scale features of the ow, such as the
ow rate ratio in junctions and the pressure distribution. Moreover, dierent inow/outow
boundary conditions in domains with multiple outlets may lead to a variation of local features
such as wall shear stress (WSS) even at regions located far away from the terminal vessels.
Hence, whenever it is possible, in simulations of arterial ow in patient specic geometries,
corresponding patient-specic inlet and outlet boundary conditions should be applied as well.
For the inlet boundary condition, typically patient specied pulse mass ow is applied [52,
50, 46, 47, 43, 44, 45, 48, 49]. The importance of outow boundary conditions has been long
recognized and some works have attempted to model the peripheral arterial network in order
to derive more realistic pressure boundary conditions at the outow [52, 53, 54, 55]. Four
main approaches of outlet boundary conditions, constant pressure, resistance, Windkessel
model and impedance boundary conditions are briey reviewed. Constant pressure boundary
conditions are the simplest boundary conditions mainly used in 1D, 2D, and 3D simulations
for steady and unsteady ows with a single outlet. Also these boundary conditions are used
for steady ow simulations in domains with multiple outlets [56]. The pressure boundary
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conditions have limitation in computational simulation of pulmonary arterial circulation,
which provides physiologically incorrect results. Resistance boundary conditions is based on
the assumption of a linear dependence between the pressure and ow rate at each outlet.
Resistance boundary condition has been applied for ow simulation in 1D, 2D, 3D domains
with multiple outlets [55, 53, 54, 52]. Comparing to presume boundary conditions, the
resistance boundary condition is equivalent to constant pressure boundary condition for
steady ow simulations but have their advantages in unsteady ow simulation. Due to
the complexity of pulmonary circulation, resistance boundary condition is more expensive
than the pressure boundary condition, since the integral of velocity at each outlet must be
computed at each time step.
Windkessel models are computational system developed to examine the load generated
by the heart for pumping blood through the pulmonary or systemic arterial system, and set
up the relation between blood pressure and ow in the pulmonary artery. There are several
variations of the Windkessel model for boundary conditions. The most common is the three-
element Windkessel model [57, 11]. This type of boundary condition can be applied to both
steady and unsteady ow simulations. It has been shown that the three-element Windkessel
model generally overestimates systemic arterial compliance [58, 59].
Impedance boundary conditions was investigated in Olufsen [52] and it involves an
analytical approach for modeling the outow boundary conditions. In impedance boundary
conditions, arterial networks are considered as 1D tree like structure. The linearized ow
equations is solved analytically, and the ow is assumed as time periodicity. The impedance
boundary conditions are more accurate, realistic than other three boundary conditions and
can be applied to 1D, 2D, or 3D ow simulations in domains with multiple outlets. The
disadvantage is that simulations is needed to run more cycles before they achieve convergence,
which makes the simulation expensive, particularly in multiple dimensional models [55, 55].
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1.2.5 Current Treatment for PAH
The purpose of PAH research, including clinical, experimental and basic study, is to
nd out the possible treatment of the PAH. Unfortunately there is no cure for PAH currently.
Understanding the pathogenesis through these research have found out possible treatment
of PAH to improve the symptoms and hemodynamics. Generally the treatments of PAH can
be divided into two groups, the conventional treatment and specic pharmacologic therapies.
Either conventional treatment or specic pharmacologic therapies must be taken carefully
to patients, due that individual patient might have dierent pathology, complication and
symptoms.
Conventional treatment include the oxygen, anticoagulant, diuretics and cardiac gly-
cosides [60]. Oxygen therapy is useful to patients who have chronic pulmonary hypertension
by maintaining the oxygen saturation (above 90%) during both rest and exercise. Research
by Roberts et al [61] has shown that treatment with 100% oxygen is a selective pulmonary
vasodilator in patients with pulmonary hypertension, which can improve the cardiac index
and PVR. The eect of anticoagulation on pulmonary arteries include decreasing the possible
thromboembolic complications and reducing in situ intraarterial microvascular thrombosis,
which are found pathologically in patients with PAH [62]. Diuretics benet to the RV preload
is good to patients with some right heart dysfunction secondary to PAH [62]. Although the
cardiac glycosides are used to treat PAH for long term and they have some benet to specic
patients [63], the benet to general PAH patients is not veried yet.
Specic treatments include the calcium-channel blockers, prostacyclin therapy, prosta-
cyclin analogues, endothelin-receptor antagonists, nitric oxide and type 5 phosphodiesterase
inhibitors [62]. In pulmonary arterial vessels, a decrease in calcium relaxes vascular smooth
muscle and yields less contraction, and the contraction of vascular smooth muscle deter-
mines the vasoconstriction during PAH. The calcium-channel blockers through changing the
calcium in pulmonary arteries perform vasodilation and decrease distal resistance, which
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has benet to PAH. Prostacyclin produced by vascular endothelium can potentially relax
vascular smooth muscle. Intravenous prostacyclin is expensive, has short half life, sensitive
to potential of hydrogen, complicated to deliver and causes pain during deliver which limit
its use to treat PAH. The prostacyclin analogues is more stable with longer half-life, allows
them to be delivered via alternate routes and have more advantages in PAH treatment than
intravenous prostacyclin. Endothelin-receptor antagonists is working on the endothelin-1
which plays an important pathogenetic role in the development and progression of PAH by
modulating both vasoconstriction and proliferation [62]. Nitric oxide and type 5 phosphodi-
esterase inhibitors are working on the nitric oxide in vascular vessels which is a vasodilator
and directly relaxes vascular smooth muscle [61]. All specic treatments try to treat the PAH
through vasodilator which reveres the vasoconstriction in PAH, although cells or materials
addressed are dierent.
Due to PAH complicated symptoms and unclear pathologies, it might not sucient
to treat PAH with one therapy. A combined treatment using dierent therapies based on
the patients' symptoms and hemodynamics possibly provide better treatment on PAH. The
pulmonary vascular remodeling resulting from smooth muscle cell plays a important role in
PAH progression and future treatment of PAH should be targeted to reverse or reduce this
remodeling process, or decrease the eect of the smooth muscle cell on vascular remodeling.
1.3 Proposed Hypotheses in Evaluating PVR, PVS, Proximal Geometry on
Hemodynamics and RV Afterload in PAH Progression
Most of the recent research [23, 28, 50, 26] obtains or investigates one individual prop-
erty and its relationship to PAH. But for PAH condition, there are several phenomena oc-
curred internationally. In many vascular diseases, it is increasingly appreciated that arterial
stiening is an important factor in determining adverse cardiovascular events [64, 65, 66, 67].
Increased arterial pulse pressure, a direct consequence of stiening, has been used to guide
pharmaceutical treatment for a variety of systemic vascular diseases. Importantly, the large
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elastic arteries, although often thought to be simply passive conduits, are known to partici-
pate in the regulation of pulsatile arterial ow [42, 68].
We suggest to setup numerical models to study the combined eect of PVR, PVS,
ow rate, WSS, input impedance and geometry on PAH. By simulating multiple models,
each with unique properties, we will attempt to isolate the eects of each property inde-
pendently on PAH, and to determine, for example, which are more or less important. The
goal of our research is to determine mechanical associations between input impedance and
changes in PVS, PVR, ow rate, WSS with these models. Our hypothesis is that PVS,
PVR have dierent impact on the proximal and distal ow eld, including pulsatile ow
rate, waveform, WSS and input impedance. The mean pulmonary arterial pressure (mPAP)
is directly aected by PVR while no aected by PVS. The input impedance has good re-
lation with PVS and the higher harmonics of impedance will have good correlation with
true stiness. WSS is determined by the ow eld and arterial structure, and aects the
endothelium behavior in the arterial luminal surface. Although some of these properties
are beginning to be considered in clinical research, such studies lack detailed and systemic
clinical methods to nd out relationships between vascular pathologies and their associated
hemodynamics and artery mechanics. The methods are limited by screening tools and tech-
niques. Through non-specic anatomically information on pulmonary vascular structure, we
can create a realistic computational simulation environment, which can be used to test our
theories regarding various associations between hemodynamic and mechanical variables in
the pulmonary vasculature of both humans and animals. Through these types of studies,
we should obtain a high level of mechanistic information regarding how the structural adap-
tations undergone by the pulmonary vasculature during pulmonary vascular disease aects
hemodynamics, vascular function and subsequently impedance and RV afterload.
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1.4 Potential Clinical Contribution
Although PAH is a relatively rare disease, it has catastrophic implications for individual
and with serious societal ramications. Describing hemodynamic PAH as a highly prevalent
occurrence that aects millions of people would be accurate but unnecessarily alarmist: Most
cases are associated with comorbid conditions, of which PAH is a relatively minor component.
On the other hand, it is equally clear that clinically important PAH encompasses far more
than the traditionally discussed population with IPAH and includes all patients with chronic
thromboembolic disease, disproportionate PAH in hypoxic lung conditions, residual PAH
after optimal treatment of left heart disease, and various miscellaneous causes.
Previous and current investigations on PVS, input impedance and RV power have
found PVS to be an important contributor to ow energy power, and thus, afterload. These
investigations focus on the analysis of clinical data, which requires long term observation
and inspection of a great number of individuals, whose clinical pathogenesis may not be the
same. It is dicult within clinical studies to vary stiness/resistance in an example system,
and it is impossible to separate the contributing eects of stiness and ow from clinical
results. Such predictive capabilities may be useful in helping evaluate the ecacy of newly
designed therapies that may target particular components of RV afterload such as proximal
vascular stiness or distal vasoconstriction, and as a tool to examine disease progression, and
others. Our model's ability to predict impedance, pulsatility, and general shear conditions
from only a handful of common clinical parameters, both on individual and grouped bases
may make it useful in the future as a screening tool, if such parameters can be estimated on
a non-invasive basis.
Chapter 2
Impact of Pulmonary Vascular Stiness and Vasodilator Treatment in Pediatric
Pulmonary Hypertension: 21 Patient-Specic Fluid-Structure Interaction
Studies
2.1 Introduction
PAH is a complex disease, associated with a progressive increase of PVR [1] and sus-
tained elevation of mean pulmonary artery pressure (mPAP), which together contribute
to right heart dysfunction. PAH is primarily considered to be a small vessel disease, and
distal vessel vasculopathy is generally considered a major contributor to its progression
[69, 70, 71, 72]. Recent research has focused on changes in upstream pulmonary arteries as
well. In patients with PAH, proximal arterial wall remodeling can result in increased PVS
[73, 37], which decouples the upstream vasculature from the right ventricle and increases RV
loading. In systemic vessels, studies have shown that upstream vascular stiness is prog-
nostic of disease outcomes [74], and this idea is beginning to be evaluated in the pulmonary
circulation as well [25, 24, 26]. These early studies suggest that vascular stiening plays an
important role in the development and progression of PAH; however, very little is known
about how increasing PVS impacts the pulmonary circulation and its role in progressing
the disease. Collagen and elastin are extracellular matrix components that bear the vast
majority of arterial wall stress and determine the passive stiness of the conduit pulmonary
arteries. Recent studies of hypoxia-induced pulmonary hypertensive calves [28] indicate that
adaptations of the continuum and geometric properties of elastin, in response to PAH, elevate
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the circumferential stiness of proximal pulmonary arterial tissue while maintaining some
degree of vascular elasticity. Thus, elastin remodeling of upstream pulmonary vessels may
be an adaptation that maintains the vascular Windkessel and preserves RV-vascular cou-
pling. Studies have also shown that vascular collagen accumulation occurs under severely
hypertensive conditions [75]. Collagen remodeling may be an adaptation to preserve pul-
monary vascular integrity at very high pressures; however, collagen due to its stretch-locking
function would cause a loss to Windkessel function and decouple the RV from the upstream
pulmonary vasculature [28]. These ideas continue to be explored in basic research studies.
The eects of upstream vascular remodeling on clinical status have yet to be determined.
In particular, the question of how increasing PVS aects RV performance and pulmonary
vascular hemodynamics remains open. Recent studies have shown that changes in hemody-
namics, especially wall shear stress, can cause marked changes in endothelial and smooth
muscle activity within the vasculature. For example, Li et al [76] showed that increasing
WSS pulsatility caused distal pulmonary vascular cells to release vasoconstrictive and pro-
liferative factors. Further, given the signicant half-life of elastin [77], vasodilator infusion,
the most common clinical treatment of PAH, may not alleviate chronic increases in stiness
due to elastin remodeling, while collagen-induced stiening due to moderate worsening could
strongly aect a patient's overall hemodynamic state.
Here we explore the above questions and investigate the relationships amongst vascular
stiness, patient outcomes, and hemodynamics using a patient-specic, two dimensional (2D)
numerical model meant to represent the conduit pulmonary arteries. Patient-specic model
parameters of cardiac output, PVR, and main pulmonary artery diameter are obtained from
standard clinical measurements, while pulmonary vascular stiness is estimated with a new,
validated echo-based method. The modeling technique is rst validated through compari-
son of 21 patient-specic models with clinically measured mean pulmonary artery pressure
(mPAP) and input impedance (Z) [26, 23]. The impacts of resistance and stiness on power
and global hemodynamics are related to previously dened pediatric PAH outcomes [26]
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with predictive models based on averaged clinical parameters from 30 patients grouped into
three outcomes categories. Finally, two predictive models examine our hypothesis regarding
the importance of vascular stiness in two clinical scenarios, vasodilator treatment and acute
moderate vasoconstriction leading to collagen engagement.
2.2 Numerical Model
Our group and others have developed a variety of numerical models to simulate and
predict cardiovascular hemodynamics; these ranges from extremely complex models that
include three-dimensionality, non-linearity in material properties and uid rheology, and fully
bi-directional uid-solid coupling, to simple one-dimensional models that simulate bulk ow.
Although each type of model has advantages and disadvantages, we believe that two factors
are critical to moving such techniques from research to clinic: developing a unique model for
each patient that is validated using that patient's data; and achieving reasonable solution
times to allow the model to be used on many patients. Here we take a compromise approach
by reducing the complexity of the model to allow reasonable solution times yet answer the
questions posed, but maintaining patient-specicity and validation over a larger number
of patients. A two dimensional (2D) axisymmetric pulmonary artery model is developed
to represent the proximal pulmonary arterial circulation in children for both normotensive
and hypertensive states. Figure 2.1 shows the schematic of the two dimensional symmetric
pulmonary artery model with a diameter D: the artery has a total length of 0.2 m and a
lumen diameter of 10 mm. The thickness of the vessel wall is approximately 10% of the
local diameter [78]. We intended this modeled section to be representative of the upstream,
elastic pulmonary arteries.
Fluid Domain: Blood is modeled as an incompressible, laminar, Newtonian uid
with a viscosity 3.5 mPas and density 1050 kg/m3. Prior to model initialization, no trans-
mural pressure exists with zero ow; thus no additional dynamic external uid loading is
considered. The stress vector is continuous across the uid structure boundary, where the
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non-slip condition is applied to the uid velocity vector. The inlet ow rate is transient, with
pulse shape obtained from clinical measurements (described below). The outlet boundary
condition of the ow domain is specied as a resistance boundary condition [52]
R = P=Q (2.1)
in which R is PVR and dened as PVR = (mPAP-PWCP)/CO [79]. Here PWCP is
pulmonary wedge capillary pressure. P and Q are the mean pressure (mm Hg) and ow
rate (L/min) at the outlet boundary. For validation the model is scaled with specic patient
size and we used PVR instead of PVRI (PVRI = PVRBSA) as an exit condition. Our
outcomes models, which are not patient specic, are sized for patients with a BSA about 1
m2; more detail regarding model scaling is below (\Use of Clinical Data in the Model").
Figure 2.1: The schematic of the two dimensional symmetric pulmonary artery model.
Solid Domain: The pulmonary artery wall is considered as an incompressible isotropic
linear elastic model with density 1200 kg/m3 and Poison's ratio 0.48; incremental modulus
is specied on a patient-specic basis and will be discussed further below. The artery wall is
constrained to move only radially at each end, while exterior and interior boundary surfaces
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are loaded with constant uniform pressure and uid pressure/shear stress, respectively.
Solution Procedure: The CFD-ACE multiphysics package (CFD Research Corpo-
ration, CA, USA) is used to perform mesh generation, develop the numerical model, and
to solve the governing equations for uid ow and structural motion with the nite volume
and element methods, respectively [80]. At the initial condition, the velocity and pressure
in the uid domain is set to 0, while the arterial wall has no displacement. In the process of
numerical calculation of uid domain the uid velocities and pressures are computed with
boundary conditions (inlet, outlet, axisymmetric axis and uid/wall interface) by using the
continuity equation (Eq. 2.2) and the Navier-Stokes equations (Eq. 2.3) at every iterative
step.
r  (~V ) = 0 (2.2)

@(ui)
@t
+ r  (~V ui) =  @P
@xi
+r  (rui) (2.3)
here  is the density, t is the time, ~V is the velocity vector in two dimension, ui is
the velocity in i direction, P is the pressure, xi is the coordinate, and  is the viscosity of
blood in artery. A FORTRAN subroutine was used to implement the resistance boundary
condition in CFD-ACE. At every iterative step, rstly the ow rate at the outlet boundary
is calculated by summing the ow rates at all outlet boundary mesh nodes. The ow rate at
each mesh nodes can be computed by the longitude velocity and mesh length at each volume
mesh (due to the 2D axisymmetric model). Then the total ow rate at the outlet boundary
is obtained by tensing 2, which indicates total ow rate in a full 3D pulmonary artery. The
outlet pressure is calculated by using the resistance boundary condition in Eq. 2.1. Finally
the outlet boundary is set as the pressure boundary condition in model to compute the uid
eld in uid domain. The nite volume method is used to calculate the uid eld which
requires a volume mesh and calculates the uid eld at every volume cell in the mesh.
At the boundary conditions on the uid structure interface, the uid has no-slip bound-
22
ary condition and the displacements of the uid and solid domain are the same. The pressure
in uid domain and stress in structure are coupled at the interface with equilibrium. These
conditions are given in by
df = ds
~uf = ~us
f  nf = s  ns
(2.4)
here d is the displacement,  is the stress tensor, and f and s represent uid and solid.
In the process of numerical calculation of structure domain the shear stress and pressure
of the ow at the uid/ structure boundary are used to evaluate the displacement of the
arterial wall at a given iterative calculation step [80]. The equations of linear elasticity
are used to calculate the arterial wall deformation. The equations are equation of motion,
strain-displacement equations (Eq. 2.6) and constitutive equations (Eq. 2.7). The equation
of motion is an expression of Newton's second law (Eq. 2.5). Hooke's law (Eq. 2.7) is used
for the elastic material to calculate the material behavior.
r   = u (2.5)
" =
1
2
[ru+ (ru)T ] (2.6)
 = C : " (2.7)
here  is the Cauchy stress tensor, " is the innitesimal strain tensor, u is the dis-
placement vector, C is the fourth-order tensor of material stiness,  is the mass density, T
represents the transpose of matrix and u represents the second derivative of displacement
vector with respect to time.
Standard transnite interpolation (TFI) scheme is applied to determine the interior
node distribution based on the motion of the boundary nodes. Figure 2.2 demonstrates the
interior node (i,j) re-construction and calculation based on the motions dened at edges
through the 2D re-meshing in Eq. 2.8 [80]
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here, dx and dy are displacements, function f is a linear interpolation function that is dened
by the ratio of the edge length. TFI scheme is fast and computationally (memory and time)
inexpensive but only available for structured zones.
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Figure 2.2: The grid structure and TFI methodology
In the computational simulation, the structural dampening plays an important role in
reduce the amplitude of oscillations in pulmonary artery. CFD-ACE uses a spectral damping
method which is named Rayleigh damping whereby viscous damping is incorporated by
specifying a percent of critical damping. This approach forms the damping matrix C as a
linear combination of the mass and stiness matrices (Eq. 2.9).
C = M + K (2.9)
here  is the mass and  is the stiness proportional damping coecients respectively.
The critical damping fraction is express as
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 = 0:5[=! + !] (2.10)
Here ! is the frequency of oscillatory and typical values of fraction are between 0.5%
and 15%. In simulation, the values of  and  are 0 and 0.01 respectively and well reduce
the amplitude of oscillations.
Once the deformation of arterial wall is calculated, the velocity and displacement of the
arterial surface are imposed back to the uid, yielding the altered ow domains and boundary
(uid structure interface) velocity in the next iterative calculation, which means that the uid
and the structure are interacting. The uid velocities and pressure are computed again in
the altered domain and the updated uid forces on the arterial wall are applied as boundary
conditions of the motion of the structure.
The Conjugate Gradient Squared (CGS) and Preconditioning solver [81] is used to
calculate velocity. The Algebraic Multi-Grid (AMG) solver [82] is applied to process pressure
correction and CGS solver is applied to the stress calculation [80]. Here the procedure of
CGS, CGS+precondtioning and AMG solver is described. The CGS algorithm is applied to
the system
A = S (2.11)
which represent continuity equation in uid eld and equation of motion in structure eld.
At the initialization (n = 0), the formula 2.11 is expressed as
r0 = S   A0
q0 = p 1 = 0
p 1 = 1
(2.12)
For the nth sweep (n  1)
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n = r0
T rn
n =
n
n 1
un = rn + nqn
pn = un + (qn + npn 1)
n = Apn
n = r0
Tn
n =
n
n
qn+1 = un   nA(un + qn+1)
n+1 = n + n(un + qn+1)
(2.13)
where rn+1 is the residual at the nth sweep. The convergence rate of the above CGS solver
depends on the spectral radius of the coecient matrix and can be eectively accelerated
by preconditioning the system. This preconditioning is accomplished by transforming the
formula 2.11 by
P 1A = P 1S (2.14)
where P is a preconditioning matrix which approximates A [80].
The basic idea of a AMG solution is to use a hierarchy of grids, from ne to coarse,
to solve a set of equations, with each grid being particularly eective for removing errors
of wavelength characteristic of the mesh spacing on that grid [80]. Firstly on the ne grid
(original grid) residual is obtained after performing few iterations, then iterations is per-
formed on the coarse grid to obtain corrections, with the ne-grid residual being imposed
as a source term. Corrections to the ne grid is interpolated and the ne grid solution is
updated. Finally the entire procedure is repeated until the residual is reduced to the desired
level. AMG solver uses only the equation matrix itself (not the geometry) to generate the
coarse grids.
The under relaxation used in CFD-ACE is a constraint on the change of a dependent
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or auxiliary variable from one solution iteration to the next to maintain the stability of the
coupled, non-linear system of equations. There are two under relaxations used, one is the
inertial relaxation and the other is the linear relaxation [80]. The inertial relaxation (rang
0-1) is applied to variables directly solved during the iterative procedure, which include
velocities here. Linear relaxation (rang 0-1) is applied to all variables that are computed
during the solution procedure, which include pressure, density, viscosity and grid motion.
Decreasing inertial relaxation or increasing linear relaxation can perform a fast convergence
during iteration, but the stability is lower. Here we used velocities relaxation value of 0.2
in inertial relaxation, pressure of 0.05 and grid motion of 0.03 in linear relaxation which
produce relative stability and fast convergence. Our model uses incompressible ow with
constant viscosity, the density and viscosity relaxations will not be considered and set as 1
in simulation.
This iterative calculation continues until both the ow and structure variables converge.
The converge criterions for all calculated parameters are 10 4. The numerical calculation
proceeds to the next time step with rst order Euler time integration and then the above
procedure is repeated. We tried two types of time integration methods, rst order Euler
and second order Crank-Nicolson methods and both methods perform good results for the
simulation if we applied the same proper time step (2 ms). Here we use rst order Euler to
save more computation time. The ow chart of the numerical calculation process with uid
structure interaction model is shown Fig. 2.3.
A rectangular mesh is generated for the axisymmetric geometry containing 4221 uid
nodes and 804 solid nodes, with 201 nodes on the uid-structure boundary 2.4. Mesh vali-
dation was carried out by taking a 1.5 rened mesh (9331 uid nodes, 1806 solid nodes);
comparisons displayed a maximum of 1% dierence in pressure and velocity in the uid do-
main. Time integration utilized a rst order Euler approach with a time step of 2 ms. Time
convergence was veried by halving the time step (1 ms). We compared the uid pressure
and velocity at the end of simulations (typical 5 cardiac cycles) with and without this rened
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Figure 2.3: The ow chart of the numerical calculation process with uid structure interac-
tion model.
time step, and found less than a 1% change in uid pressure or velocity at nine dierent
locations (a 33 array of points dened in the axial direction at the inlet, midpoint, and
outlet and along the radial direction at the axis of symmetry, halfway between the axis and
the wall, and at the arterial wall). Time convergence was veried by halving the time step
(1 ms) and showed a dierence less than 1%. Each model is run for a total time of 3 seconds
to insure that the simulations are convergent in the transient inlet condition: the resistance
boundary condition coupled with wall stiness allows for uid storage, which can take sev-
eral cardiac cycles to become periodic. The details about the solution of uid and structural
equations can be referred to our previous work [83, 50, 84]. In the solution procedure, we use
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the CFD-ACE algebraic multigrid solver for the uid equations and a direct (linear) solver
for the structural equations.
Figure 2.4: The mesh generation for the two dimensional symmetric pulmonary artery model.
2.3 Clinical Data Acquisition
After institutional review board approval and informed consent and assent had been
obtained, data were obtained from 30 patients during routine cardiac catheterization that
is part of the regular evaluation and treatment of these subjects at the Children's Hospi-
tal in Denver, CO. Pressure measurements were made with standard uid-lled catheters
(Transpac IV, Abbot Critical Care Systems) within the main pulmonary artery (MPA). Two
echocardiographic measurements (Vivid 5, GE Medical Systems) were used: 1) PW Doppler
velocity measurements were taken within the midsection of the MPA with a commercial
ultrasound scanner from a parasternal short-axis window; and 2) right pulmonary arterial
(RPA) diameter was obtained from Color M-Mode Tissue Doppler Images (CMM-TDI) of
the RPA wall from the suprasternal short-axis view. More detail regarding data acquisition
may be found elsewhere [26, 23]. Cardiac output (CO) was measured by Fick's method
with measured oxygen consumption in cases where intracardiac shunts were in place and by
thermodilution otherwise. Two derived measures were calculated from the measured data
according to previously published methods: pulmonary vascular input impedance (Z) was
computed from pressure and PW Doppler [23], while an estimate of vascular elastic modulus
was obtained from pressure and RPA diameter [30].
All patients were hypertensive and were grouped according to a \soft" one-year outcome
based on their initial and follow-up world health organization (WHO) functional status
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[1, 26]. The three outcomes categories generally indicate 1) improvement, taken as a change
of 1 functional class for the better; 2) slight worsening, corresponding moving from class
1!2 or 2!3; and 3) signicantly worsening or death, the former indicated by an increase of
>2 functional classes. Patients who maintained functional class were categorized according
to severity: constant class 1 denoted an outcome of 1; constant class 2 or 3 denoted an
outcome of 2; and constant class 4 yielded an outcome of 3.
2.4 Use of Clinical Data in the Model
The model parameters are cardiac output, elastic modulus, PVR, MPA diameter, ar-
terial wall thickness, and transient ow prole. The rst three of these are directly obtained
or estimated on a patient-specic basis from clinical data, whereas the last three are either
approximated from clinical data on a patient specic basis or use a single source and are
explained in more detail as follows. Additionally we describe our method for modeling the
stiening process, which incorporates clinical stiness measurements and observations from
animal studies.
Model Diameter: The model diameter should correspond to MPA diameter, given
that our input ow condition corresponds to the total pulmonary ow; however we were
unable to obtain its dimensions from our existing ultrasound dataset. MPA diameter is
estimated from measured RPA diameter (using CMM-TDI as noted above) by using an
average MPA/RPA diameter ratio of 1.58 in diastole [85, 86]. For validation, each model
has a patient-specic MPA diameter estimated from direct measurements of the RPA, while
the outcomes models were sized for a BSA of 1.0 m2. To obtain the proper size for these
models we found the average diameter (2 cm), ow (4 L/min), and heart rate (100 Hz) of
ten patients (5 in OC1, 4 in OC2 and 1 in OC3) with BSA in the range 0.91.1 m2 . We
note that only 5 patients of these 10 patients are listed in Table 2.1; the other 5 patients
were missing a single parameter (such as CO, etc) rendering them unusable in our validation
study.
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Model Thickness: Because the pulmonary artery wall thickness, for children is
within the uncertainty of trans-thoracic ultrasound (i.e., 1-3 mm) it is dicult to directly
measure from the clinical images. Again, we obtain a reasonable estimate from reported
thickness values for dierent arteries and the associated artery wall thickness-to-diameter
ratios [87, 78, 88, 89], which ranged from 0.08 to 0.11. We used 0.10, an average of these
ratios, for the main pulmonary artery in our calculations, as we did in previous computational
work [50]. Use of an average thickness was shown to provide an acceptable estimate of elastic
modulus in a validation study of the CMM-TDI method [30]. Note that elastic modulus is
estimated on a patient specic basis using the methods outlined in this work [30].
Inlet Flow Condition: Inlet ow velocity is assumed to be spatially constant, with
magnitude determined from patient-specic or generic ow time histories and current in-
let cross-sectional area. For the validation models, ow time histories were obtained by
combining mean ow measurement (i.e. cardiac output) with MPA midsection blood veloc-
ity (obtained from PW Doppler as noted above); this procedure corresponds to our previ-
ous methods for approximating transient ow from velocity using an area correction factor
[26, 23, 90]. Because only a single prole is used here (unlike previous work, which examined
multiple cardiac cycles independently), PW Doppler velocity histories in ve consecutive
cardiac cycles were taken, averaged ( ut = 
5
n=1ut;n=5, u is the measured velocity, t indicates
at the same time in ve cardiac cycles), and scaled to the known mean cardiac output with
the area correction factor to obtain a nal ow time history. For the three outcomes models,
a single ow time history was obtained from spatial and temporal velocity elds measured
by phase-contrast magnetic resonance imaging (PC-MRI) [91] in a single, healthy patient
with BSA = 1.0. Preliminary work has shown that with preserved cardiac function, this
temporal waveform is similar between patients at dierent states of disease [91].
Modeling of the Stiening Process: As noted in the introduction, our recent
animal model study of vascular stiening [28] suggests there are two stages of the process:
elastin remodeling and collagen engagement. The rst of these approximately doubles the
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(roughly) linear elastic Young's modulus of the artery wall at smaller stretch ratios. The
latter is a nonlinear eect that occurs due to the engagement of vascular collagen at higher
stretch, and yields a substantial increase (>10 in some cases) in the incremental material
modulus above the engagement stretch (1.5 for normal and hypertensive animals). Each
change is modeled as a single linear incremental modulus as measured clinically as noted
above. Here the stretch ratio is dened as ratio of instantaneous lumen diameter to initial
lumen diameter.
Table 2.1: Parameters from clinical measurements to develop patient-specic numerical mod-
els.
0.562713.31132.07611.3PHT90
0.94204.80854.28913.1PHT87
1.763210.6753.05019.7PHT86
0.91185.481844.57713.1PHT85
0.242016.7951.11359.10PHT84
1.30274.401006.17817.2PHT83
0.825625.02902.212617.2PHT80
1.101913.1591.510017.4PHT78
1.10234.641333.911419.1PHT66
0.282410.81280.91505.69PHT65
0.53187.73342.311012.4PHT63
0.513415.5572.21078.06PHT62
1.355512.8803.87524.2PHT61
0.282812.2742.11205.06PHT59
1.208015.42385.211211.2PHT58
0.303424.51441.41308.85PHT55
1.336214.63224.39230.3PHT53
0.47189.131102.06912.2PHT52
0.673710.21943.69417.1PHT50
0.734421.02362.19713.6PHT49
0.92236.57293.59716.7PHT48
BSA
(m2)
mPAP
(mm Hg)
PVR
(mm Hg/(L/min))
Elastic Modulus
(kPa)
CO
(L/min)
HR
(bpm)
MPA Diameter (mm)Patient
2.5 Post Numerical Data Processing
The WSS is calculated and the derivation of WSS from velocity is performed by tting
the velocity data with a polynomial function [92]. Both four-point and three-point polyno-
mial data tting functions are used. Comparison of the WSS between these two methods
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shows that three-point polynomial data tting function is accurate enough for WSS calcu-
lation in pulmonary artery (Fig. 2.5). Details regarding the calculation of impedance from
pressure and ow waveforms may be found in our previous works [23, 26]. The input modulus
impedance modulus Z and phase  are dened as
Z(!) =
jP (!)j
jQ(!)j (2.15)
(!) = (!)  '(!) (2.16)
here ! is the frequency, jP j is the modulus of the pressure spectrum, jQj is the modulus
of the ow spectrum,  is the pressure phase, and ' is the ow phase. From the impedance
data two parameters were extracted: the zero harmonic impedance value (Z0) and the sum
of the impedance values from the rst 2 harmonics (Z1+Z2). The zero harmonic impedance
value correlates with distal vascular resistance, and the sum of the impedance values from the
rst 2 harmonics correlates with PVS. Higher harmonics of impedance (>second) contained
suciently high uncertainty to preclude inclusion for statistical analysis or clinical relevance
although they quantify stiness and may contain additional information such as reection
strength. The characteristic resistance (Zc) was estimated by averaging the impedance mod-
ulus from its rst minimum up to the eighth harmonic [93, 94].
RV power (the rate of ventricular work) comprises potential energy and kinetic energy.
Kinetic energy has been shown to account for a small fraction of the total ventricular power
and is neglected here [42, 68]. The mean power (mean energy per unit time) was calculated
as
WM = P0 Q0 (2.17)
where P0 and Q0 are the zero-frequency components of the pressure and ow moduli, re-
spectively. The oscillatory power (pulsatile energy per unit time) was calculated as
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Figure 2.5: Comparison of WSS by using three-point and four-point polynomial data tting
functions for OC1.
WO =
1
2
3X
n=1
jQnj2jZnj cosn (2.18)
here n represents the harmonic of the fundamental frequency. Finally, total RV power was
calculated as
WT = WM +WO (2.19)
The Wormsley number is a dimensionless expression of the pulsatile ow frequency
in relation to viscous eects. For pulsatile ow condition, the velocity prole is aected
by frequency, which is related to the Womersley number that expresses pulse frequency in
relation to viscous eects.
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 = D
q
!= (2.20)
here D is diameter of artery, ! is the angular frequency of the oscillations,  is uid
density and  is the viscosity.
2.6 Results
2.6.1 Model Validation
To validate the artery model, 21 patient-specic simulations (age range 4 months-17
years, median age 6 years, 11 females) were performed, and the computed rst harmonic
modulus of input impedance (Z1) and computed mPAP were compared to clinical measure-
ments. Table 2.1 provides the patient-specic parameters that determined model geometry,
main arterial lumen diameter and estimated wall thickness which is 0.1 of the local lumen
diameter, inlet rate (heart rate (HR) and cardiac output (CO)) material properties (in-vivo
elastic modulus) and exit conditions (PVR). The pulmonary vascular resistance (PVR) was
obtained based on the fast Fourier transform [23].
Comparison of the numerical mPAPN results to clinical mPAPC measurements is shown
in Fig. 2.6. A linear regression between the clinical and numerical results yields y = 0.938 x
+ 1.299, R2 = 0.969 (p < 0.05), which suggests that measures are in good agreement. Com-
parison of numerical and clinical input impedance moduli (Z1) for all patients is shown in
Fig. 2.7. Good agreement is seen in the linear regression between clinical and numerical Z1:
y = 0.744 x + 0.683, R2 = 0.825 (p < 0.05). The numerical Z1 are smaller than the clinical
Z1 in most cases (18 of 21 cases), which we believe is due to limitation of linear constitutive
model in use; when the linear model is used instead of the more realistic nonlinear model,
any collagen engagement is ignored and an incremental measure of stiness is lower in the
hypertensive condition. As a result, numerical Z1 is smaller than that obtained from clinical
measurements. Given these comparisons of mPAP and input impedance modulus Z1 be-
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tween the numerical simulation and clinical measurements, the model appears to reasonably
represent global hemodynamics through the use of patient-specic model parameters.
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Figure 2.6: Comparison of the mean main pulmonary arterial pressure between numerical
(mPAPN) and clinical (mPAPC) results.
2.6.2 Outcomes-Specic Models
Three outcomes-specic models, referred to as \OC1", \OC2" and \OC3" for outcome
1 through 3 respectively, were created to examine global hemodynamic dierences between
the outcomes categories. For this set of simulations, group-averaged clinical data from a
total of 30 patients who were previously divided into the three outcomes categories were
used to construct the models (Table 2.2). Model OC1 has an elastic modulus of 90 kPa and
pulmonary vascular resistance index (PVRI) [26] of 7.3 mm Hg/(L/min) (n=17); model OC2
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Figure 2.7: Comparison of the input impedance modulus Z1 in pulmonary normotensive and
hypertensive states.
has averaged elastic modulus of 150 kPa and PVRI of 12.7 mm Hg/(L/min) (n=10); and
model OC3 has averaged elastic modulus of 270 kPa and PVRI of 25 mm Hg/(L/min) (n=3).
Figure 2.8 shows the inlet ow rate from the clinical MRI data before and after polynomial
data tting. Table 2.2 provides the parameters of MPA diameter, HR, CO, elastic modulus
and PVR, which are used as input variables to develop patient-specic numerical models for
three groups and are based on the clinical measurements of 21 patients. Figure 2.9 shows
the comparison of the blood outow, stretch ratio, wall pressure and WSS as a function
of time during one cardiac cycle for the three outcome-specic models. Although the pulse
outow rates are almost the same, the stretch ratio of the arterial wall, arterial mean pressure
and pulse pressure increase from category 1 to 3. Stiness has clear and direct eects on
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the pulsatility in the pulmonary circulation. When the elastic modulus increases 167%
(OC1!OC2) and 300% (OC1!OC3) the pulse pressure similarly undergoes increases of
172% and 294% respectively. Table 2.2 lists the ow rate, wall pressure and power for three
outcomes models. We see that the ratio of oscillatory to total power is relatively constant for
the three categories; generally these WO=WT values are higher than clinical measurements
in the PAH conditions for children [23], but are lower than those reported for adults [42]. It
has been proposed that the WO=WT is not only determined by the PVS and PVR, but also
aected by the heart rate [42] and thus the higher heart frequency in children (1.7 Hz)
leads to an overall decrease in WO=WT compared to adults (1 Hz) ([68].
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Figure 2.8: The inlet velocity from the clinical data before and after polynomial data tting.
Figure 2.10 shows the comparison of the input impedance modulus for the three out-
comes models. It is well known that identication of the input impedance moduli in higher
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Figure 2.9: Comparison of the blood outow, stretch ratio, wall pressure and WSS as a
function of time during one cardiac cycle for three outcome categories in PAH.
Table 2.2: Comparisons of ow rate, wall pressure and power for three outcomes states in
PAH.
Category OC1 OC2 OC3
Elastic modulus (kPa) 90 150 270
PVR (mm Hg/(L/min)) 7.30 12.7 25.0
Mean/Pulse ow rate (L/min) 4.00/2.52 4.00/2.42 4.00/2.18
Mean/Pulse wall pressure (mm Hg) 28.7/17.2 49.8/29.6 98.4/50.5
Mean/Oscillatory power (mW) 253/46.8 441/82.8 873/158
Ventricular power (mW) 300 524 1031
harmonic is problematic, as noise on pressure and ow signals aects higher harmonics [95].
Higher PVS and PVR logically cause higher input impedance in the harmonics that char-
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acterize stiness and resistance, respectively: the input impedance modulus Z0 corresponds
exactly to the resistance applied as the outow boundary condition, while Z1 and Z2 increase
as the elastic modulus increases.
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Figure 2.10: Comparison of the input impedance modulus for three outcome categories in
PAH.
2.6.3 Eect of Collagen Engagement on Category 2 Patient
Our averaged outcomes parameters for OC2 and OC3 displayed a clear dierence in
their elastic modulus. However, even slight increases in OC2 pressures could result in passive
stiening; here we test the hemodynamic consequences of a moderate acute increase in PVR
causing an increase in collagen ECM engagement in, and signicant stiening of, the conduit
arteries. Starting with the OC2 scenario, we model a moderate 20% increase in resistance
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increase and a change in elastic modulus to the OC3 value of 270 kPa, to determine the
potential hemodynamic and work requirements associated with this change.
Figure 2.11 compares the blood outow, stretch ratio, wall pressure and WSS as a func-
tion of time during one cardiac cycle for OC2 and collagen engagement; clearly the latter is
associated with increased pulmonary arterial pulsatility in the ow rate, stretch ratio, wall
pressure and WSS. Table 2.3 lists ow rate, wall pressure and power for OC2 and collagen
engagement of OC2. Elastic modulus and pulse pressure increase by approximately 180%,
while similarly PVR and mPAP increase approximately 120%, again displaying the clear
association between the parameters and their respective pressures. The mean and oscilla-
tory powers are increased 121% and 150% respectively with the collagen eect. Thus this
signicant increase in stiness yields moderate impacts on the total power, but signicantly
alters pulsatility.
2.6.4 Eect of Vasodilator Treatment on Category 2 Patient
The objective of PAH treatment is to decrease the pulmonary arterial pressure, which
in turn is associated with lower RV afterload and power. Vasodilator treatment can reduce
distal resistance in some patients; however if such patients have undergone elastin-based
proximal vascular remodeling as seen in prior studies of the hypoxic calf [28], their afterload
would retain high-stiness characteristics. To examine this situation we modeled a condi-
tion with elastic modulus of 150 kPa and a PVR of 7.3 mm Hg/L/min corresponding to an
outcome 2 patient who strongly responded to vasodilator treatment. Figure 2.12 displays
blood outow, stretch ratio, wall pressure and WSS as a function of time during one cardiac
cycle for OC2, OC2 with vasodilator treatment and OC1. After the vasodilator treatment,
decreased distal resistance yields reductions in mean power to nearly the level of OC1, while
oscillatory power is nearly the same as that of OC2 (Table 2.3). The latter represents moder-
ate component of the total power, which is substantially reduced and the apparent objective
of vasodilator therapy is achieved. Although the modeled OC2 vasodilator treatment reduces
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the mean pressure and wall deformation, its hemodynamic state clearly does not match the
OC1 state, with the former exhibiting higher ow, pressure and WSS pulsatility.
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Figure 2.11: Comparison of the blood outow, stretch ratio, wall pressure and WSS as a
function of time during one cardiac cycle for OC2 and collagen engagement.
Table 2.3: Comparisons of ow rate, wall pressure and power for OC2, collagen engagement
and vasodilator of OC2.
OC2 Collagen Vasodilator
engagement treatment
Mean/Pulse ow rate (L/min) 4.00/2.42 4.00/3.54 4.00/4.16
Mean/Pulse PAP (mm Hg) 49.8/29.6 60.2/51.6 28.7/28.7
Mean/Oscillatory power (mW) 441/82.8 534/124 254/76.8
Ventricular power (mW) 524 658 331
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Figure 2.12: Comparison of the blood outow, stretch ratio, wall pressure and WSS as a
function of time during one cardiac cycle for OC1, OC2 and vasodilator treatment of OC2.
2.7 Discussion
Results from the outcomes-specic models show that percentage increases in pulse
pressure move in lockstep with percentage increases in the elastic modulus. This corresponds
to our expectations that increasing PVR is associated with increased mPAP while increasing
stiness increases pressure pulsatility. In contrast, WSS pulsatility tends to decrease in the
stier condition, and is likely due to the fact that the vessel is more greatly distended in
the severe condition (i.e. greater stretch ratio), resulting in a greater cross sectional area
for the same ow and thus, an overall reduction in velocity and WSS. Interestingly, these
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observations of reduced WSS have also recently been made in clinical MRI of PAH patients
[91, 96]. This reduced WSS is reminiscent of ow conditions in atherosclerotic arteries [97],
suggesting that mechanotransduction in these proximal vessels could possibly play a role in
disease progression [98].
Previous work has shown that the proximal stiness is an important contributor to
ventricular power [42] in adults with PAH, while for children, Weinberg et al. [23] observed
the eect of proximal stiness on the total RV power is lower (<10%); our results lie be-
tween these clinical observations. Although the majority of the RV power requirement is
due to mean power and thus PVR, these results conrm the idea that the neglect of os-
cillatory power can signicantly (20-30%) underestimate the total power. Improving the
power estimate appears to have the greatest importance in evaluating disease treatment
and progression; for example, in both OC2 perturbation studies (vasodilator and collagen
engagement), oscillatory power increased as a total percentage of the total power.
Impedance has previously been shown to be a useful prognostic, but it has previ-
ously required invasive measurement of pressure and ow. Our model's ability to predict
impedance, pulsatility, and general shear conditions from only a handful of common clinical
parameters, both on individual (in the validation above) and grouped bases may make it
useful in the future as a screening tool, if such parameters can be estimated on a non-invasive
basis [26, 99, 22].
The collagen engagement and vasodilator treatment perturbation model results conrm
that focusing only on elevations or reductions in PVR neglect more signicant hemodynamic
changes. The modeled vasodilator treatment result highlights the ineectiveness of mPAP-
reducing vasodilator therapy to reduce hemodynamic pulsatility in the setting of permanently
remodeled upstream pulmonary vessels, although under current clinical guidelines such a
patient would be seen as having highly reactive pulmonary vessels. Similarly, the collagen
model posits that changes in pulsatility and mean-to-pulsatile power ratio are possible even
with relatively minor increases in resistance. If stiening plays a signicant role in outcomes
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and thus, disease progression, these models suggest it two mechanisms: through changes
in ow and pressure pulsatility, and through increasing required RV power. Given recent
ndings relating changes in ow pulsatility to changes in pulmonary endothelial cell signaling
[100, 76], this appears a reasonable hypothesis, and places equal importance of stiening on
power and hemodynamic derangement.
2.8 Limitations
Here the eect of vascular stiness on pulmonary ow in progressing PAH is examined
using a patient-specic and patient-validated 2D numerical model. Comparison of 21 model
runs to their corresponding clinical data show good agreement between model predictions of
impedance and mean PA pressures and clinical measurements, thereby validating the model.
PAH worsening was modeled using data from three PAH outcomes groups; these show not
only the expected increase in mean PA pressures, but an increase in pressure pulsatility
as well. Interestingly, chronically increasing PA pressures decreased WSS, indicating the
impact of increased PA areas on WSS was greater than the impact of increased PVS. For a
patient having moderate PAH with elastin-based upstream vascular remodeling, moving from
elastin-dominant upstream vessel behavior to collagen-dominant behavior caused substantial
increases in pressure, pressure pulsatility and WSS pulsatility. For the same patient, reducing
PVR through a simulated vasodilator to a value equivalent to mild PAH did not decrease
pressure pulsatility and in fact increased WSS pulsatility dramatically. Overall, these results
suggest a close association between PVS and hemodynamics and those treatments should
target decreasing or reversing upstream vascular remodeling in addition to decreasing mean
pressures.
Chapter 3
Vascular Stiness on Pulmonary Arterial Flow in Normotensive and
Hypertensive States in Children
3.1 Introduction
PAH is an important determinant of morbidity and mortality in children. It is associ-
ated with a progressive increase of pulmonary vascular resistance and sustained elevation of
the pulmonary artery pressure which causes right heart dysfunction. Invasive measurement
of pulmonary vascular ow and pressure provides the hemodynamic status of the pulmonary
circulation for children with PAH. PAH is primarily considered to be a small vessel disease
and distal, small vessel vasculopathy is generally considered a major contributor to its pro-
gression [69, 71, 101, 72]. However, it has recently been postulated [74, 25] that proximal
arterial stiness, which aects coupled blood ow and artery distension in the great systemic
arteries may also profoundly aect the overall pulmonary hemodynamics as well as disease
outcomes [24, 25, 26]. This suggests that pulse pressure and arterial WSS may have impor-
tant roles in the development and progression of PAH. In patients with PAH, arterial wall
remodeling can result in decreased arterial compliance [37, 73], causing an increase in pulse
ow rate, pulse pressure, arterial wall shear stress, wall pressure and ventricular power load.
Clinicians are primarily interested in PVR, which is the mean pressure drop across
the circuit divided by the mean ow through it [1], in that it is believed to well-quantify
right RV afterload; PVR is also considered as the primary determinant of mortality. Of
course, the PVR only qualies the steady state resistance because it is computed with mean
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values, and it therefore ignores the dynamic impact of the stiness or the impedance on
the pulmonary circuit [102, 103, 104]. The stiness quanties the dynamic aspects of the
pressure and ow, and they aect pulsatility within the pulmonary artery. The importance of
including dynamic (PVS) components on evaluation of PAH has been recently investigated
and research showed that the PVS provides a better prediction of the mortality. Several
approaches are employed to study the relation between PVS and PAH mortality. Mahapatra
et al. [24] proposed a capacitance index of stroke volume divided by pulmonary pulse pressure
to predict probability of survival in IPAH, while Gan et al. [25] investigated proximal
pulmonary artery stiness, in terms of area distensibility and noninvasively assessed relative
area change (RAC), calculated as relative cross-sectional area change, and found that it
predicts mortality in patients with PAH. Hunter et al. [26] not only investigated the eect
of PVS on the pulmonary circuit but also the total afterload, which provides the relation
between the cardiac function and the pulmonary hemodynamics.
The input impedance, which provides both static (PVR) and dynamic (PVS) infor-
mation, has shown promise as a superior measure of vascular function. It is dened as
the ratio of the harmonic pressure to the harmonic ow rate, and characterizes RV after-
load comprehensively, reecting proximal arterial compliance, distal vascular resistance, and
wave-transmission properties [105, 104, 106, 11]. RV power, consisting of both a mean com-
ponent and an oscillatory component, quanties the ventricular power needed to move blood
through the pulmonary vasculature [39, 40, 41]. The input impedance, PVS and PVR pro-
vide a more comprehensive means of evaluating PAH and assessing vascular reactivity than
that currently available through PVR measurements alone. Previous and current investiga-
tions on the pulmonary vascular stiness (PVS), input impedance and RV power [42, 23, 26]
have found PVS to be an important contributor to power, and thus, afterload. The symp-
toms of pulmonary hypertension are explained by a decrease in cardiac output caused by an
afterload induced RV failure. These previous and current investigations focus on the analysis
of clinical data, which are useful but currently lacks sucient detail to establish relation-
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ships between changes in vascular stiness and their eects on local and global pulmonary
hemodynamics.
Here through our developed two dimensional (2D) numerical artery model of the pul-
monary main arterial we determine if it oers insight into structure function relationships in
circulation in children for both normotensive and hypertensive states. The hemodynamics
simulated by the simple pulmonary model are examined and compared with clinical data. It
is expected that the numerical results on input impedance are agreement with clinical data.
The impacts of PVS on the vascular ow, arterial pressure, impedance and ventricular power
are studied quantitatively.
3.2 Numerical Model
The two dimensional (2D) axisymmetric pulmonary artery model is developed to rep-
resent the proximal pulmonary arterial circulation in children for both normotensive and
hypertensive states, which is the same as Fig. 2.1 shown in chapter 2. We intended this
modeled section to be representative of the upstream, elastic pulmonary arteries.
Fluid Domain: The blood properties, including density, viscosity, inlet, outlet and
interface between uid and solid domain are the same as previous model. The inlet ow ve-
locity is transient, with peak velocity and pulse shape obtained from clinical measurement by
using phase contrast magnetic resonance imaging (PC-MRI). A fast low-angle shot (FLASH)
gradient echo sequence was used to obtain retrospectively phase velocity map in the through-
plane direction (Siemens Magnetom Avanto, Munich). Velocity encoding (VENC) values
were adjusted according to the maximum velocities encountered during scout sequences to
optimize the velocity map resolution. Figure 3.1 shows the inlet ow velocity from the clin-
ical data before and after polynomial data tting for a 5 years old female. Here the high
order polynomial data tting method is applied to make the inlet ow velocity sequential
and smooth during cardiac cycles. The heart rate is 120 beat/min which provides a mean
blood ow rate of 2 L/min. The outlet boundary condition of the ow domain is specied
48
as a resistance boundary and the resistances of 7.5 and 20 mm Hg/(L/min) are used for the
normotensive and hypertensive states respectively, as noted in Table 3.1.
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Figure 3.1: The inlet velocity from the clinical data before and after polynomial data tting.
Solid Domain: The pulmonary artery wall is considered as an incompressible isotropic
linear elastic model with density 1200 kg/m3 and Poison's ratio 0.48. The parameters of
vascular stiness used for the normotensive and hypertensive states are listed in Table 2.1.
Pulmonary vascular stiness of 60 kPa is examined in the normotensive state and 140 kPa
is applied in the hypertensive state as the baseline stiness. The artery wall is constrained,
such as it may move only radially, while exterior and interior boundary surfaces are loaded
with constant uniform atmospheric pressure and uid pressure/shear stress, respectively.
The CFD-ACE multiphysics package (CFD Research Corporation, CA, USA) is used to
perform mesh generation, develop the numerical model, and to solve the governing equations
for uid ow with the nite volume method and the equations of motion for the structure
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Table 3.1: Parameters for the normotensive and hypertensive states.
PVS (kPa) PVR (mm Hg/(L/min))
Normotensive 60 7.5
Hypertensive 140 20
with the nite element method. A rectangular mesh is generated and the total mesh number
is 4221 in uid domain and 804 in solid domain. The mesh validation is carried out by
taking a 1.5 rened mesh (9331 in uid domain and 1806 in solid domain). comparisons
displayed a maximum of 1% dierence in pressure and velocity in the uid domain. Time
integration utilized a rst order Euler approach with a time step of 2 ms. Time convergence
was veried by halving the time step (1 ms). We compared the uid pressure and velocity at
the end of simulations (typical 8 cardiac cycles) with and without this rened time step, and
found less than a 1% change in uid pressure or velocity at nine dierent locations (a 33
array of points dened in the axial direction at the inlet, midpoint, and outlet and along the
radial direction at the axis of symmetry, halfway between the axis and the wall, and at the
arterial wall). Time convergence was veried by halving the time step (1 ms) and showed a
dierence less than 1%. A total time of 4 second is calculated for all cases to make sure the
simulations are convergent. The details about the solution of uid and structural equations
can be referred to our previous work [107, 84, 50].
3.3 Model Validation
To validate the two dimensional (2D) symmetric pulmonary artery model, two ap-
proaches, the transient midline velocity of the blood ow and the input impedance modu-
lus are carried out and compared to those from the clinical investigations in normotensive
and hypertensive states. Clinical data acquisition of the midline velocity time history was
obtained semiautomatically from the recorded PW Doppler signals [26]. The detail com-
putation of the input impedance based on the measurements input pressure and ow rate
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is listed in our group's previous work [26]. Comparison of the transient midline velocities
between the numerical and clinical results in normotensive and hypertensive states is shown
in Figure 3.2. Due to the similarity of the transient midline velocities between the nor-
motensive and hypertensive states, and the experimental error of the clinical measurements,
we just compare normotensive and hypertensive midline velocities with one clinical midline
velocity. Results show that the transient midline velocities between numerical and clinical
results agree each other very well; of interest is the earlier arrival of a reection wave in the
hypertensive waveform (at 3.7 second rather than 3.8 second), which arrives during systole
and is reminiscent of the so-called \ying W" shape, i.e. mid-systolic notching, frequently
used as a non-invasive indicator of PAH [108].
Then the input impedance modulus is carried out and obtained from the numerical
simulations and clinical measurements. Comparison of the input impedance modulus in
pulmonary normotensive and hypertensive states is shown in Figure 3.3. Z0 presents the
pulmonary vascular resistance therefore it is the same for numerical and clinical results.
In the normotensive and hypertensive state, Z1 and Z2 from the numerical simulation are
closed to those from clinical data signicantly. From the comparisons of the transient mid-
line velocity and input impedance modulus between the numerical simulation and clinical
measurements, we can say that this the two dimensional (2D) symmetric pulmonary artery
model is very valuable and can presents the realistic pulmonary main arterial circulation in
children for both normotensive and hypertensive states. Based on the parameters from the
measured clinical data, including PVR, PVS and inlet ow rate proles, we can use this 2D
model to predict the unmeasured properties of pulmonary artery in children both for nor-
motensive and hypertensive states. Then the change of clinically unmeasured properties of
the pulmonary artery in children can be tracked which are used to guide the clinical studies.
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Figure 3.2: Comparison of the midline velocities between numerical and clinical results.
3.4 Results
The blood outow, wall displacement, wall pressure, WSS and input impedance mod-
ulus in the normotensive state (PVS: 60 kPa, PVR: 7.5 mm Hg/(L/min)) and hypertensive
state (PVS: 140 kPa, PVR: 20 mm Hg/(L/min)) are carried out. The position considered
for the wall pressure and WSS is located exactly between the inlet and outlet boundary at
the arterial lumen and only the eighth converged cycle is presented. Figure 3.4 shows the
comparison of the blood outow, wall displacement, wall pressure and WSS as a function
of time during one cardiac cycle in pulmonary normotensive and hypertensive states. In
the hypertensive state, the wall pressure is higher than that in the normotensive state while
the outlet peak ow rate and WSS are about the same. The peak arterial wall pressure
is 25.6 mm Hg in the nomotensive state while 62.0 mm Hg in the hypertensive state. Al-
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Figure 3.3: Comparison of the input impedance modulus in pulmonary normotensive and
hypertensive states.
though a higher PVS in the hypertensive state decreases the arterial wall motion, the higher
PVR makes more blood storage in the artery. As a result of both higher PVS and PVR in
the hypertensive state, the arterial wall maximum displacement is about the same as that
in the normotensive state. The pulse/mean outow ow rate, pulse/mean wall pressure,
mean/oscillatory power and ventricular power in the normotensive and hypertensive states
are compared and listed in Table 3.2. The pulse/mean wall pressure in the hypertensive state
all are higher than those in the normotensive state. The mean outow rate is kept constant
in normotensive and hypertensive states because of constant inlet pulsatile ow. All of the
mean, oscillatory and ventricular powers in the hypertensive state are higher than those in
the normotensive state. The ratio of the oscillatory power WO to the ventricular power WT
is carried out. In the normotensive state, WO=WT is 8.60%, while in the hypertensive state,
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WO=WT is 5.94%. The WO=WT agree with clinical measurements in the normotensive and
hypertensive states [23] for the children. The WO=WT is not only determined by the PVS
and PVR, but also aected by the heart rate. High heart frequency in children (2 Hz) could
decreases WO=WT which is lower than those (1 Hz) in the adults' human bodies [68]. The
simulated hypertensive condition, with higher resistance and stiness, clearly yields higher
total afterload in the pulmonary circulation.
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Figure 3.4: Comparison of the blood outow, wall displacement, wall pressure and WSS as
a function of time during one cardiac cycle in pulmonary normotensive and hypertensive
states.
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Table 3.2: Comparisons of ow rate, wall pressure and power in normotensive and hyper-
tensive states.
Normotensive Hypertensive
Mean/Pulse ow rate (L/min) 2.00/3.02 2.00/2.18
Mean/Pulse wall pressure (mm Hg) 15.3/19.7 40.0/43.0
Mean/Oscillatory power (mW) 66.4/6.24 176/11.1
Ventricular power (mW) 72.6 187
3.4.1 Prediction of Advanced Hemodynamic Features
To investigate the eect of PVS values on the blood outow, wall pressure, WSS,
and input impedance modulus in the normotensive state, the numerical simulations are
carried out for three dierent PVS of 40, 60 and 80 kPa. The results of the blood outow,
wall pressure, WSS, and input impedance modulus are presented. Figure 2.10 shows the
comparison of the blood outow, wall displacement, wall pressure and WSS as a function
of time during one cardiac cycle for dierent PVS in the normotensive state. As the PVS
increases, the peak outlet ow rate, the wall pressure and WSS increase respectively while
the wall displacement decreases. The times for the maximum ow rate, wall displacement
and wall pressure come earlier as the PVS is increased. Figure 3.6 shows the comparison
of the input impedance modulus for dierent PVS in normotensive state. Higher PVS also
logically causes higher input impedance in the harmonics that characterize stiness. The
input impedance modulus Z0 is close to 7.5 mm Hg for all three dierent PVS, and represents
the PVR applied as the outow boundary condition. Z1 and Z2 which are aected by PVS
increase slightly as the PVS increases in the normotensive state. The pulse/mean outow ow
rate, pulse/mean wall pressure, mean/oscillatory power and ventricular power for dierent
PVS in normotensive state are compared and listed in Table 3.3. As the PVS increases, the
pulse ow rate and pulse pressure increases, while the mean ow rate and mean pressure are
almost kept constant. When the PVR is kept constant, the PVS only aect pulse ow rate
and pulse pressure signicantly. The WO=WT are 3.67%, 8.60% and 14.0% for the PVS of
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40 kPa, 60 kPa and 80 kPa in the normotensive state respectively. The oscillatory power
is related to the PVS and the eect of oscillatory power on the right ventricular power is
increased as the PVS increases.
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Figure 3.5: Comparison of the blood outow, wall displacement, wall pressure and WSS as
a function of time during one cardiac cycle for dierent PVS in normotensive state.
Table 3.3: Comparisons of ow rate, wall pressure and power in normotensive state.
PVS (kPa) 40 60 80
Mean/Pulse ow rate (L/min) 2.00/2.30 2.00/3.02 2.00/3.62
Mean/Pulse wall pressure (mm Hg) 15.26/13.5 15.28/19.7 15.32/24.9
Mean/Oscillatory power (mW) 65.7/2.50 66.4/6.24 67.0/10.9
Ventricular power (mW) 68.2 72.6 77.9
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Figure 3.6: Comparison of the input impedance modulus for dierent PVS in normotensive
state.
Finally the eect of PVS values on the blood outow, wall pressure, WSS, and input
impedance modulus in the hypertensive state are carried out for three dierent PVS of
120, 140 and 160 kPa and the results of the blood outow, wall pressure, WSS, and input
impedance modulus are presented. Figure 3.7 shows the comparison of the blood outow,
wall displacement, wall pressure and WSS as a function of time during one cardiac cycle for
dierent PVS in the hypertensive state. As the PVS increases, the peak outlet ow rate,
the wall pressure and WSS increase respectively while the wall displacement deceases. The
times for the maximum ow rate, wall displacement and wall pressure come earlier as the
PVS is increased. Figure 3.8 shows the comparison of the input impedance modulus for
dierent PVS in hypertensive state. As same as that in the normotensive state, higher PVS
also logically causes higher input impedance in the harmonics that characterize stiness.
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The input impedance modulus Z0 is close to 20 mm Hg for all three dierent PVS, and
represents the PVR applied as the outow boundary condition. The pulse/mean outow ow
rate, pulse/mean wall pressure, mean/oscillatory power and ventricular power for dierent
PVS in hypertensive state are compared and listed in Table 3.4. As the PVS increases, the
pulse ow rate and pulse pressure increases, while the mean ow rate and mean pressure are
almost kept constant. When the PVR is kept constant, the PVS only aect pulse ow rate
and pulse pressure signicantly, which are the same as those in the normotensive state. The
WO=WT are 4.13%, 5.94% and 7.80% for the PVS of 120 kPa, 140 kPa and 160 kPa in the
hypertensive state respectively.
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Figure 3.7: Comparison of the blood outow, wall displacement, wall pressure and WSS as
a function of time during one cardiac cycle for dierent PVS in hypertensive state.
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Figure 3.8: Comparison of the input impedance modulus for dierent PVS in hypertensive
state.
Table 3.4: Comparisons of ow rate, wall pressure and power in hypertensive state.
PVS (kPa) 120 140 160
Mean/Pulse ow rate (L/min) 2.00/1.90 2.00/2.18 2.00/2.48
Mean/Pulse wall pressure (mm Hg) 40.0/36.9 40.0/43.0 40.0/48.6
Mean/Oscillatory power (mW) 176/7.58 176/11.1 176/14.9
Ventricular power (mW) 183.6 187 191
3.4.2 Discussion
The input impedance can be consistently and easily obtained from PW Doppler and a
single catheter pressure measurement. However, the relationship between the harmonics of
impedance and vascular stiness cannot be determined in a complex arterial tree. This paper
presents a simple computational approach to relate vascular stiness (elastic modulus) to the
59
harmonics of impedance. Comparison of normalized input impedance modulus Z1, Z1 +Z2,
and characteristic impedance Zc as a function of elastic modulus for all normotensive and
hypertensive states is shown in Fig. 3.9. The characteristic resistance Zc was estimated by
averaging the impedance modulus from its rst minimum up to the eighth harmonic [94, 93].
Here the case of PVS = 40 kPa and PVR = 7.5 mm Hg/(L/min) is used as baseline and
impedance moduli are normalized. As elastic modulus increases, all Z1, Z1 + Z2, and Zc
increase respectively and linearly. The regression lines and regression factor for Z1, Z1+Z2,
and Zc are listed and either Z1, Z1 + Z2, or Zc has the linear relation with elastic modulus.
This model and results can be employed to test linear relationship between input impedance
and PVS in Weinberg and Hunter's previous work [23, 26].
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Figure 3.9: Comparison of normalized input impedance modulus Z1, Z1 + Z2, and charac-
teristic impedance Zc as a function of elastic modulus for all normotensive and hypertensive
states (Baseline case: PVS: 40 kPa, PVR: 7.5 mmHg/(L/min)).
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The importance of vascular stiness on RV afterload has been more recognized in hy-
pertension management strategies [109, 110, 111, 112, 24] . Relationship between arterial
stiening and pulmonary hypertension are well established [113, 114]. Right ventricular func-
tion is exquisitely sensitive to any increases in afterload, which include increased pulmonary
arterial pressure or PVR. Clinically, the output of the RV decreases manifestly as a progres-
sive decrease in RV ejection, which has particular signicance in situations where increases
in RV afterload occur. It has been established that incorporation of stiness in diagnosis
yields better prediction of patient outcomes [24, 25, 26]; because inclusion of this property
better characterizes total load, we have hypothesized that impedance better predicts right
ventricular power. Figure 3.10(a) shows comparison of normalized ventricular power, input
impedance Z0, Z0+Z1 and Z0+Z1+Z2 as a function of elastic modulus for all normotensive
and hypertensive states (Baseline case: PVS: 40 kPa, PVR: 7.5 mmHg/(L/min)). The sig-
nicant increase between normotensive and hypertensive states is caused by increased PVR
from 7.5 to 20 mm Hg/(L/min). In hypertensive state, work loaded on RV is higher than
that normotesnive state, which can make RV failure suddenly. As the hypertension becomes
more serious, RV will be loaded more work and RV fails more suddenly. Either Z0, Z0 + Z1
or Z0+Z1+Z2 has the linear relation with elastic modulus. Z0+Z1 can be employed to do
best track total ventricular power compared to Z0 alone or Z0 + Z1 + Z2, when a factor 0.9
is added to the Z0 + Z1. Study the relation between input impedance and total ventricular
power provides input impedance is a good correlate of total ventricular power.
Pulmonary arterial stiness is pressure-dependent and, in essential hypertensive pa-
tients, the increased arterial stiness is in part due to higher distending blood pressure [115].
Here the relation between total ventricular power, pulmonary arterial pulse and mean pres-
sure and PVS is studied qualitatively. The linear relation between total ventricular power,
pulse pressure/mean pressure and elastic modulus is shown in 3.10(b). As elastic modulus
increases, the pulmonary arterial pulse pressure increases linearly, while the mean pressure
has good track compared to the ventricular power. The pulse and mean pressure in the pul-
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monary artery can be directly measured in clinic. Through the linear relation between pulse
pressure and PVS, mean pressure and ventricular power, pulmonary pressure may be used
to determine the area correction factor to convert pulse pressure for PVS in future studies.
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Figure 3.10: Comparison of normalized ventricular power, (a) input impedance Z0, Z0 + Z1
and Z0 + Z1 + Z2, (b) pulse and mean pressure as a function of elastic modulus for all nor-
motensive and hypertensive states (Baseline case: PVS: 40 kPa, PVR: 7.5 mmHg/(L/min)).
The WO=WT agree with clinical measurements in the normotensive and hypertensive
states [23]. The WO=WT is not only determined by the PVS and PVR, but also aected
by the heart rate. High heart frequency in children (2 Hz) could decreases WO=WT which
is lower than those (1 Hz) in the adults' human bodies [68]. The simulated hypertensive
condition, with higher resistance and stiness, clearly yields higher total afterload in the
pulmonary circulation.
3.5 Limitations
This study is mainly focusing on eect of PVS and PVR on hemodynamics and RV
afterload in normotensive and hypertensive conditions, so other parameters is kept consistent
in both conditions to reduce their inuence. The cardiac output, which expressed as inlet
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ow rate in the model is the same for both normotensive and hypertensive states. Clinical
investigation shows that the cardiac output is lower in hypertensive state than that in nor-
motensive state for the same age children [23]. Here the same inlet ow rate in normotensive
and hypertensive states is employed in order to study the eect of PVS and PVR on PAH
without impact of ow rate. Another limitation is the PVS used in model, which is not
directly obtained from clinical measurements. However, the values of PVS are in the ranges
of normotensive and hypertensive conditions which make our model representing respective
conditions. Other simplications, including boundary conditions, etc, can be refereed to
previous discussion.
Chapter 4
Inuence of Distal Resistance and Proximal Vascular Stiness on Vascular
Impedance and Hemodynamics in Pulmonary Hypertension: A Computational
Study with Validation Using an Animal Model
4.1 Introduction
PAH is a complex disease, associated with a progressive increase of PVR)[1] and sus-
tained elevation of mPAP) which together contribute to right heart dysfunction. Much work
remains to fully understand the pathogenesis of PAH, which is still uncertain for most PAH
forms [116], with complicated interplay between cellular and molecular features, tissue me-
chanics, and even environmental factors. Although many recent developments employing
clinical and experimental measurements have investigated symptoms [91, 96, 30, 28] to fur-
ther elucidate the roles of pulmonary arterial mechanics and hemodynamics, the individual
relative importance of the components of PVR, PVS, geometry and cardiac function are
unclear in disease progression. In addition, while current PAH treatment focuses on the
vasodilation, it is unknown whether or not other treatment targets might benecially impact
right ventricular function, and as a result improve of PAH treatment.
Changes in the distal circulation are traditionally considered the fundamental eect of
PAH. For example, the distal pulmonary vascular bed can undergo remodeling resulting from
growth of smooth-muscle cells (SMCs), which narrow and restrict distal pulmonary vascular
geometry. Recent studies of vascular cellular features and tissue mechanics have shown
that lumen obliteration of, medial hypertrophy, and adventitial proliferation contribute the
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diameter decrease and thickness increase in PAH [117, 118, 119]. In severe PAH, a layer of
myobroblasts and extracellular matrix also develops between the endothelium and internal
elastic lamina, further thickening and narrowing pulmonary arterial walls [120]. The eects
of these changes, along with persistent vasodilation, are most clearly seen in decreasing right
ventricular (RV) cardiac output and increasing mPAP [69, 41, 23], which together indicate
increased PVR. In turn, PVR is believed to well quantify RV afterload. These pathologies
are currently treated with vasodilators, and further indenties the traditional association
between distal geometry, PVR and RV afterload, as well as RV failure in PAH progression.
Although vascular distal remodeling and distal vessel vasculopathy are generally con-
sidered the only major contributors to PAH progression [71, 101, 72, 69], recent clinical
[25, 30, 24] and basic science [121, 28] research has found that stiness is predictive of
disease outcomes and that proximal remodeling is also present, respectively. Remodeling
chronically alters the stiness of the proximal arteries through combined changes in their
extracellular matrix composition and thickness [24]. Proximal stiness has been shown to 1)
regulate pressure and ow wave velocities in the pulmonary bed; 2) aect afterload indepen-
dent of resistance; and 3) aect proximal WSS and thus potentially have impacts on cellular
signaling through mechanotransduction [91]. These observations indicate that evaluation
of upstream vascular stiness should play a relatively more important role in pulmonary
hypertension diagnosis than currently considered, with the current diagnostic PVR quanti-
fying only the static component of pulmonary hemodynamics. However, it is still unclear
about how increasing PVS impacts the pulmonary circulation and its role in progressing
the disease, or correlation between changes of proximal diameter/thickness with levels of
vascular remodeling as well as PAH progression. Although currently there are no treatments
aimed towards reducing on proximal stiness, an interesting question is raised whether such
treatments would be benecial to improve PAH treatment.
Progression of pulmonary hypertension involves continuously changing vascular hemo-
dynamics and remodeling of the proximal and distal arteries. It is understandably dicult
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to investigate an individual parameter's eect on PAH in an in-vivo study. Here we pro-
pose a research procedure to examine PAH progression by dividing it into four stages. At
each stage we only consider system changes due to varying a single pulmonary vascular pa-
rameter, from PVR, elastic modulus (EM) and arterial thickness, starting with the control
condition. We evaluate the role of these key parameters in modulating input impedance and
hemodynamics using the two-dimensional (2D) pulmonary vascular model based on in-vivo
and ex-vivo measurements obtained directly from normal and chronically hypoxic neonatal
calves [28, 120]. By comparing these animal measurements to 17 calf specic models, we
rst validate our numerical results on mPAP and rst harmonic of input impedance (Z1).
We then perform studies to assess the eects of PVR, EM, and arterial thickness on the ar-
terial pressure, WSS, impedance and RV power. Finally, impacts of theoretical and available
PAH treatment are examined by reversing these parameters, thereby investigating the eect
of proximal vascular remodeling on PAH if we target it for treatment, beside the vasodila-
tor. We believe this simple but validated model oers the comprehensive insight of PAH
progression and might encourage new treatment targets.
4.2 Numerical Model
Our primary intent here is to examine how hemodynamics and RV power change in
PAH progression and to determine what is relationships exist between PAH treatment eects
and these hemodynamics and RV power. To include the eects of proximal compliance we
lumped the upstream vessels into a single elastic tube, modeled in two dimensional (2D)
axisymmetric coordinates. Figure 4.1 shows the schematic of the tube model with diameter
D, thickness h and a total length of 0.1 m.
Fluid Domain: Blood is modeled as an incompressible, laminar, Newtonian uid
with a viscosity 3.5 mPas and density 1050 kg/m3. Prior to model initialization, no trans-
mural pressure exists with zero ow; thus no additional dynamic external uid loading is
considered. The normal component of the stress tensor is continuous across the uid struc-
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D/2 Fluid Domain
Arterial Wall
0.1 m
h
Figure 4.1: The two dimensional axisymmetric schematics of the pulmonary artery in calves.
ture boundary, where the non-slip condition is applied to the uid velocity vector. The inlet
ow rate is transient, with pulse shape obtained from experimental measurements, as ex-
plained below. The outlet boundary condition of the ow domain is specied as a resistance
boundary condition [52], which is shown as Eq. 2.1.
Solid Domain: The pulmonary artery wall is considered as an incompressible isotropic
linear elastic model with density 1200 kg/m3 and Poison's ratio 0.48; the elastic modules
of models were obtained from ex-vivomeasurements and are discussed further below. The
artery wall is constrained to move only radially at each end, with a load-free condition on
the exterior surface and coupled uid pressure/shear stress on the interior surface.
Solution Procedure: The CFD-ACE multiphysics package (CFD Research Corpo-
ration, CA, USA) is used to develop the numerical model, perform mesh generation, and to
solve the governing equations for uid ow and structural motion with the nite volume and
element methods, respectively. A rectangular mesh is generated for the axisymmetric geom-
etry containing 4221 uid nodes and 1005 solid nodes, with 201 nodes on the uid-structure
boundary. Mesh validation was carried out by taking a 1.5 rened mesh (9331 uid nodes,
2107 solid nodes); comparisons displayed a maximum of 1% dierence in pressure and veloc-
ity in the uid domain. Time integration utilized a rst order Euler approach with a time
step of 2 ms. Time convergence was veried by halving the time step (1 ms). We compared
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the uid pressure and velocity at the end of simulations (typical 5 cardiac cycles) with and
without this rened time step, and found less than a 1% change in uid pressure or velocity
at nine dierent locations (a 33 array of points dened in the axial direction at the inlet,
midpoint, and outlet and along the radial direction at the axis of symmetry, halfway between
the axis and the wall, and at the arterial wall). Time convergence was veried by halving
the time step (1 ms) and showed a dierence less than 1%. Each model is run for 5 cardiac
cycles to insure that the simulations are convergent in the transient inlet condition. In the
solution procedure, we use the CFD-ACE algebraic multigrid solver for the uid equations
and a direct (linear) solver for the structural equations. A serial computer system (AMD
Opteron(tm) Processor 280 2.4GHz, 2.0G memory) performed the simulations; typical wall
time for one model is about 5 hours for a simulation time of 3 seconds (5 cardiac cycles).
4.2.1 Animal Data Acquisition
The calf's data include MPA lumen diameter, thickness, elastic modulus (PVS), mean
MPA pressure (mPAP), distal resistance (PVR), cardiac output (CO), ow rate prole and
impedance. All studies were performed after approval by institutional animal care and use
committees. Seventeen newborn male dairy calves (Holstein) weighing between 35 and 50
kg were used and the experimental measurements were described in previous papers [30,
28]. To make the data acquisition process clearer, the experimental methods are described
briey here. Ex-vivo measurements were taken to obtain the MPA diameter, thickness
and elastic modulus [28]. MPA were processed into circumferential strips and tested on
a standard material testing system (MTS Insight II, Eden Prairie, MN) to obtain ex-vivo
elastic modulus [30] over a wide range of strains. The acquisition of others parameters,
mPAP, distal resistance, cardiac output, ow rate prole and impedance were used the in-
vivomeasurements [30]. A solid-state (Millar SPC-350) catheter was used to obtain pressure
waveform, while a caudal, short-axis view at the 4th intercostal space, 3-6 cm dorsal to the
elbow was used to obtain color M-mode tissue Doppler imaging (CMM-TDI) measurements
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of instantaneous velocity in main pulmonary artery. Cardiac output (CO) was measured by
Fick's method with measured oxygen consumption in cases where intracardiac shunts were
in place and by thermodilution otherwise. Finally, pulmonary distal resistance and vascular
input impedance (Z) was computed from pressure and PW Doppler [23]. Additional post-
processing is required to implement some of the in-vivo and in-vitro data described above;
this is described below.
4.2.2 Use of Experimental Data in the Model
Model Geometry and Elastic Properties: The model geometry and elastic prop-
erties, includes the diameter, thickness and elastic modulus all correspond to MPA measured
by ex-vivo methods [28]. Each of the seventeen models used in validation has a subject-
specic MPA diameter, thickness and elastic modulus with a single length of 0.1 m. We
averaged thickness and elastic modulus values from eight control and nine hypertensive an-
imals to obtain model endpoints for our progression and treatment simulations. There was
no statistically signicant change in the lumen diameter between control and hypertensive
groups and we used one averaged diameter for all simulations. These averaged values are
shown in Table 4.1 and of course indicate the true physiological changes seen during PAH
progression.
Inlet Flow Condition: The inlet condition corresponds to what we did in the clinical
models. Inlet ow velocity is assumed to be spatially constant, with magnitude determined
from calf-specic or generic ow time histories and current inlet cross-sectional area. Due
the high Wormersley number (>10), here a parabolic prole is not expected because pul-
satile ow exiting the right ventricle can not be fully developed within the MPA. For the
validation models, ow time histories were obtained by combining mean ow measurement
(i.e. cardiac output) with MPA midsection blood velocity (CMM-TDI). Velocity histories in
ve consecutive cardiac cycles were taken, averaged, and scaled to the known mean cardiac
output with the area correction factor to obtain a nal ow time history [26, 90, 23]. After
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Table 4.1: Parameters from experimental measurements to develop and validate numerical
models.
 
 No. Thickness 
(mm) 
Elastic 
Modulus (kPa) 
PVR 
(mm Hg/(L/min)) 
mPAP 
(mm Hg) 
Diameter 
(mm) 
CO 
(L/min) 
HR 
(Beat/min) 
165 3.68 72.7 4.91 18.5 16.0 3.88 114 
166 3.44 136 4.79 29.0 19.7 6.06 147 
174 3.04 138 8.88 41.0 18.2 4.62 130 
175 2.94 105 5.17 30.0 21.8 5.80 113 
176 3.34 98.4 3.83 17.5 19.8 4.70 100 
177 3.71 64.1 5.01 18.7 19.7 3.80 94 
180 3.34 77.2 3.64 17.7 19.9 5.22 114 
 
 
 
Control 
181 3.52 86.0 3.08 18.0 18.9 5.85 113 
Mean±SD  3.38±0.28 97.1±32.6 4.91±1.77 23.8±8.7    
         
167 4.19 185 14.3 68.0 24 3.45 125 
168 3.50 113 19.7 39.0 18.75 5.21 118 
169 5.12 92.6 7.48 67.0 20.4 5.12 135 
170 3.60 116 13.1 51.0 20.46 4.12 122 
171 3.98 252 12.4 65.0 22.55 3.87 131 
172 3.84 267 16.8 94.0 19.94 5.36 148 
173 3.42 187 17.5 67.0 18.8 3.52 139 
178 3.90 245 19.0 81.0 20.65 5.20 117 
 
 
 
 
Hyper 
179 3.97 136 15.6 33.4 22.22 4.83 132 
Mean±SD  3.95±0.51 177±66 15.1±3.8 62.8±19.2 20.1±1.9* 4.74±0.83* 120* 
*The averaged value for all control and hypertensive cases. 
 
calf-specic velocities time histories were computed they were used to obtain group-averaged
time-histories using the following method. The velocity proles were rst normalized in time
with respect to their cardiac cycle length; velocity at the normalized time was then averaged
on a group-wise basis (8 controls, 9 hypertension). Finally the average cardiac cycle length
was used to dimensionalize the normalized time. The heart rates is aected more sensitively
by daily activities (such as work, walk, sleep, etc) and its eect on the PAH will not be
considered in this study [68]. Here we average heart rates of all seventeen calves and use the
same heart rate for both control and hypertensive models. There was no statistically signif-
icant change in the CO between control and hypertensive groups and we used one averaged
CO for all simulations. The ow rate used in models for control and hypertensive are shown
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in Figure 4.2.
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Figure 4.2: The ow rate applied in the models for control and hypertensive conditions.
Modeling of the Stiening Process: Our recent animal model study of vascular
stiening [28] suggests there are two stages of the process: elastin remodeling and collagen
engagement. The rst of these approximately doubles the (roughly) linear elastic Young's
modulus of the artery wall at smaller stretch ratios. The latter is a nonlinear eect that
occurs due to the engagement of vascular collagen at higher stretch, and yields a substantial
increase (>10 in some cases) in the incremental material modulus above the engagement
stretch (1.5 for normal and hypertensive animals). Each change is modeled as a single
linear incremental modulus as measured clinically as noted above. Here the stretch ratio is
dened as ratio of instantaneous lumen diameter to initial lumen diameter.
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4.2.3 Post Numerical Data Processing
Matlab codes were written (MATLAB V7.7, The Mathworks, Natick, MA) to calcu-
late the WSS, input impedance, and ventricular powers. The WSS is calculated and the
derivation of WSS from velocity is performed by tting the velocity data with a polynomial
function [92]. Three-point polynomial data tting functions is applied. Details regarding the
calculation of impedance from pressure and ow waveforms may be found in our previous
works [26, 23]. Right ventricular power (the rate of ventricular work) comprises potential
energy and kinetic energy. The mean potential power (mean energy per unit time) and the
oscillatory potential power (pulsatile energy per unit time), the mean kinetic power and
oscillatory kinetic power were calculated using the Milnor's methods [42, 68].
4.2.4 Statistics
With the exception of heart rate, all data from experimental measurements are pre-
sented as meanSD. The rst harmonic impedance Z1 and mPAP computed seventeen
subject-specic models used in validation were compared with the results from measure-
ments with Student's t test. P -values refer to the probability associated with the two-tailed
Student's t test. Results were deemed statistically signicant for P -values less than 0.05
.The linear regression and Bland-Altman methods [122, 123] are employed to examine the
dierence of impedance Z1 and mPAP between numerical results and measurements. Limits
of agreement (LoA), dened as the interval expected to contain 95% of the dierences were
calculated. LoA are given by the mean dierence plus or minus 1.96 standard deviations.
95% condence intervals were taken around the LoA to evaluate their precision and consis-
tency. MATLAB codes were written (MATLAB V7.7, The Mathworks, Natick, MA) to take
the t test, linear regression and Bland-Altman analyses.
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4.3 Results
4.3.1 Numerical Model Validation
To validate the artery model, seventeen calf-specic simulations were performed, and
the computed rst harmonic modulus of input impedance (Z1) and computed mPAP were
compared to experimental measurements. Table 4.1 provides the calves based parameters
that determined model geometry (arterial lumen diameter and arterial wall thickness), inlet
ow rate (heart rate (HR) and cardiac output (CO)), material properties (ex-vivo elastic
modulus) and exit conditions (PVR). The PVR was obtained from measured ow rate (CO)
and pressures [23]. The thickness, elastic modulus, PVR and mPAP are higher in hyper-
tensive than those in control conditions (p < 0:05). There was no statistically signicant
change in the lumen diameter and CO as a result of hypertension and we used one 17 sub-
ject's averaged diameter and CO for control and hypertensive states. Comparing with those
parameters in control condition, the PVR (208%), elastic modulus (82%) and mPAP (164%)
change more than thickness (17%).
Comparison of the numerical mPAP results to experimental mPAP measurements, the
numerical and experimental impedance Z1 are shown in Figure 3. Linear regressions between
the clinical and numerical results yields y = 0:980x+0:448, R2 = 0:999 (p < 0:05) for mPAP
and y = 1:032x   0:275, R2 = 0:941 (p < 0:05) for the impedance Z1, which suggest that
measurements and numerical results are in good agreement. Bland-Altman analyses are
taken for mPAP and rst impedance Z1 between numerical and experimental results. The
Bland-Altman analyses show a biasLoA of 0.461.74 mm Hg for mPAP and 0.131.12 mm
Hg/(L/min) for rst impedance Z1. These combined analyses of linear regression and Bland-
Altman methods display reasonable agreement between numerical results and measurements.
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Figure 4.3: Comparison of the mean main pulmonary arterial pressure (mPAP) and in-
put impedance modulus Z1 between numerical (N) and experimental (E) results by linear
regression (Top) and Bland-Altman (Bottom) methods.
4.3.2 Study of PAH Progression
The eect of these parameters, PVR, EM, and proximal thickness on pulmonary hemo-
dynamics and RV power during PAH progression are studied. Here we consider the progres-
sion of PAH into four stages, control, hyper PVR (PVR: 4.91!15.1 mm Hg/(L/min)), hyper
EM (EM: 97.1!177 kPa) and hyper h (thickness: 3.38!3.95 mm). The parameters in con-
trol and hypertensive conditions are from the averaged experimental measurements in Table
4.1. Due to the preserved ow rates (CO) in models, the pressure is more reasonable and
important in predicting the pulmonary hemodynamics in this study. Figure 4.4, 4.5 and 4.6
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show comparison of proximal pressure, WSS and input impedance for all stages from control
to hypertensive conditions during PAH progression. Here wall pressure is obtained at the
middle point between inlet and outlet boundaries, the same location of WSS. Increased PVR
(208%) restricts the blood transportation in upstream arteries which elevates the mPAP and
pulsatility, however the mPAP (209%) increases higher than pulsatility (26.4%). Higher
pressure enlarges the vessel with larger cross sectional area which lowers the ow velocity; as
a result WSS is reduced both in mean (to 30.9% of control) and pulse components (to 65.4%
of control). The increased elastic modulus stiens the arterial wall and alters the pressure
pulsatility alone, at the same time the wall displacement is reduced and WSS is increased.
The thicker arterial wall has the same eect as increasing elastic modulus which increases the
pulsatility of pressure and WSS. For the impedance moduli, the Z0 is more associated with
PVR and Z1, Z2 are increased as the PVS increasing. The study of impedance of all stages
during PAH progression conrmed previous study that the rst harmonic is associated with
the PVR while the higher order harmonics of impedance are aected by PVS.
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Figure 4.4: Comparison of proximal pressure for all stages from control to hypertensive
conditions during PAH progression.
Finally the RV powers were analyzed. Figure 4.7 shows comparison of mean/oscillatory
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Figure 4.5: Comparison of proximal WSS for all stages from control to hypertensive condi-
tions during PAH progression.
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Figure 4.6: Comparison of input impedance modulus for all stages from control to hyper-
tensive conditions during PAH progression.
and RV power for all stages form control to hypertensive conditions. Two components were
calculated separately for each kind of power, one contributable to the mean pressure and ow
alone, and the other associated with the pulsations around these means. In the control con-
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dition, the oscillatory power contributes 33.2% of the total ventricular power, which is agreed
with clinical measurements for adults [42] and experimental results from other animal [124].
As the PVR increases at the beginning of the PAH progression, the mean ventricular power
increases signicantly while the oscillatory power decreases. The disagreement between os-
cillatory power and pulse pressure changes are due to the preserved cardiac function applied
in model. The PVS increases and contributes mostly to the increase of oscillatory power,
while the mean power is kept constant. As the calf progresses to the hypertensive condition,
the percentage of oscillatory power over total ventricular power decreases to 23.3%, which
agrees that in the oscillatory power contributes less to total ventricular power in hypertensive
than that in control conditions [124].
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Figure 4.7: Comparison of RV powers for all stages from control to hypertensive conditions
during PAH progression.
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4.3.3 Eect of Treatment on Proximal Vascular Remodeling
Clinical treatments of PAH mostly address on decreasing PVR, which treat the PAH
by relax the distal vascular smooth muscle cell. Here we target our treatment on individ-
ual parameter by reversing it from PAH progression, more than vasodilator to investigate if
we could fund out more PAH treatment on proximal vascular remodeling. As the same as
described in progression session, the parameters include PVR (vasodilation), elastic mod-
ulus and thickness. Three treatments are performed and in each treatment one parameter
is changed reversely from previous treatment, by changing the value from hypertensive to
control conditions. Figure 4.8 and 4.9 show the comparison of pressure and WSS for individ-
ually changing parameter in PAH treatment. The vasodilator treatment, which decreasing
the PVR could decreases the mPAP/pulse pressure dramatically. Then more treatments ad-
dressed to improve the proximal vascular remodeling are performed which reversely reduce
the elastic modulus and thickness. These treatments although do not good to mPAP but
further decrease the pulse pressure. The decreased PVR in PAH treatment increases mean
and pulsatility WSS while treatment on proximal stiness could reduce these changes. Fig-
ure 4.10 shows comparison RV power between vasodilation and proposed PAH treatments
on proximal vascular remodeling. PVR changes signicantly mean power, which has most
contribution to total ventricular power. Decreasing elastic modulus and arterial thickness
reduce oscillatory power, which although has small contribution on total power, decrease
the RV power eventually. This observation indicates that decreasing or reversing proximal
vascular remodeling could benet to PAH treatment, besides the vasodilator on PVR.
4.4 Discussion
Firstly our simple axisymmetric artery model performs great agreement with exper-
imental measurements about the mPAP and rst harmonic impedance (Z1), as a result
the model was validated. More than those, there are several other agreements between
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Figure 4.8: Comparison proximal pressure between vasodilation and proposed PAH treat-
ments on proximal vascular remodeling.
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Figure 4.9: Comparison proximal WSS between vasodilation and proposed PAH treatments
on proximal vascular remodeling.
our and exist experimental or clinical results about WSS [91, 96], RV powers [124, 42] and
impedance which were described in results session. Through this study there are several im-
portant ndings obtained and they provide evidence that hemodynamics play an important
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Figure 4.10: Comparison RV power between vasodilation and proposed PAH treatments on
proximal vascular remodeling.
role in progressing PAH. The increasing PVR yields mPAP and pulse pressure increasing
while increasing stiness contributes only to increase pressure pulsatility. WSS is associated
with the hemodynamics of pulmonary ow and tends to decrease during PAH progressing.
The vessel is more greatly distended in the severe condition (lumen diameter is enlarged),
resulting in a greater cross sectional area and reduce velocity and WSS. The observation on
changes of WSS suggests that mechanotransduction correlating the cellular, molecular, and
tissue behaviors and pulmonary hemodynamics in these proximal vessels possibly play a role
in disease progression [98].
During the PAH progression, clearly the PVR, and elastic modulus change and play
more important roles than thickness. Previous clinical and experimental studies [124, 42]
80
shows that the oscillatory power plays less when the PAH becomes worse, which is conrmed
in our proposed in setting the PAH progression. However, in the vasodilator treatment of
PAH, the oscillatory power contributes more eect on RV power and should be considered.
Therefore for treatment of PAH, especially for decreasing the ventricular power, we should
address more on proximal vascular remodeling.
The input impedance, which is derived from the pressure and ow proles in pul-
monary circulation, has a tight relation with pulmonary hemodynamics. More and more
study showed that impedance could provide useful information about the hemodynamics, as
wells as the pulmonary components, PVR and PVS. Once common clinical or experimental
parameters are obtained on a non-invasive basis [26, 99, 22], our model might be used to pre-
dict the level and degree of PAH progression, through simulating and monitoring the patients
with its ability about predicting impedance, pulsatility, and general shear conditions.
4.5 Limitations
With accurate experimental parameters, this simple 2D axisymmetric numerical model
represents a reasonable advance in calf-specic models that are applied to larger numbers
of subjects, however, as we discussed before, there are still several limitations remain. 3D
eects and complex geometry are ignored in this two dimensional axisymmetric numerical
model which inuences ow pattern in the arteries, logically aects WSS. Although dynam-
ics behavior of the arterial wall might be considered as linear during in-vivo pulsatile ow
transportation, this model simulating the PAH progression should involve the realistic vis-
coplastic behavior of the wall, especially in severe PAH condition where collagen engagement
plays more important role on vascular behavior. Resistance boundary condition simplies
the complex ow impedance presented by the distal vasculature to merely a resistance con-
dition and precludes the existence of diastolic ow. Other assumptions including constant
heart rate, CO and blood viscosity more focus our model on investigating the eect of PVR
and PVS in progressing PAH. Such simplication appears reasonable for these single branch
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models, but impedance-based outlet boundary conditions would be more realistic. Based on
all these simplications, we developed a numerical model that may be more easily imple-
mented clinically with reduced construction time and runtime.
Chapter 5
Experimental and Numerical Study of Pulse Flow Waves on Co-cultured
Vascular Cells
5.1 Introduction
In previous study PVS is known as an important predictor of cardiovascular events
and is increasingly recognized. The stiness in larger pulmonary arteries (MPA, RPA and
LPA) has inuence on the the progression of PAH and causes the distal vascular remodeling
[25], but the underlying mechanisms remain unclear. With high compliance, large arteries
decreases the pulsatility of high pulse ow to a continuous steady ow and dissipate the
high hemodynamic energy of pulsatile ow [125]. The so-called \Windkessel" eect prevents
excess rise of pressure during systole and maintains ow during diastole. During PAH pro-
gression, the large pulmonary vessels becomes stier,with the PVS increasing and decreases
capabilities of modulating ow pulsatility. This proximal vascular stiening increases the
ow pulse pressure in downstream arteries [109]. The tight relation between stiness and pul-
monary reassure has been widely investigated and used to guide pharmaceutical treatment
for a variety of vascular diseases [125].
To enable an easy mechanistic study of the relationship between upstream stiness
(PVS), ow pulsatility and small arterial remodeling, here Dr. Wei Tan's Group developed
a pulsatile ow co-culture system which, through modulation of the upstream compliance,
produces a range of arterial-like pulse ow waves which are imposed onto downstream pul-
monary arterial endothelial cells and co-cultured pulmonary arterial smooth muscle cells.
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Computational study was used as a design tool to describe the propagation and the spatial
variation of these pulse ow waves in the culture chamber to identify a uniform ow region
subject to high-delity ow waves for cell studies. The computational study also takes into
account the soft collagen surface and how this aects the spatial and temporal variation of
pulse ow waves. Additionally, ow measurements and biological analysis were performed
to ensure that cells were accurately sampled for pulsatility-specic analysis.
5.2 Methods
5.2.1 Flow System Setup and Data Acquisition
A schematic of the ow setup and ow chamber is shown in Fig. 5.1. This system
includes a blood pump, an upstream compliance-adjustment chamber, a ow meter, a culture
chamber and a reservoir which is developed by Dr. Wei Tan's group. A pulsatile blood
pump (Harvard Apparatus, Plymouth, PA)is used to generate physiologic pulse ow wave
which can be considered as the pulsatile output from the RV of heart. A compliance-
adjustment chamber is designed to simulate the elastic function of an artery and modulate
the pulsatile ow waveform. The compliance chamber has inlet and outlet valves which
provides a pressure adjustment function with air pressure release valve (Fig. 5.1C). Air in
the compliance chamber dampens the ow. The ow pulsatility is decreased with more air
in the chamber. Therefore, the level of liquid in the chamber correlates the pulsatility of the
resultant ow waveform. Figure 5.2 shows three ow waveforms created by adjustments of
upstream compliances. Real time ow rate is measured using a Precision Water Flow Meter
(Alicat Scientic, Tucson, AZ) and pressure is determined through a digital pressure gauge
(Colepalmer, Vernon Hills, IL). A ow meter is placed at the entrance to the culture chamber
to measure the experimental input and output ow waveforms. An oscilloscope (Agilent
Technologies, Santa Clara, CA) connects the ow meter and connects to a computer which
is used to acquire the ow wave. Based on these measurements the mean and transient ow
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rates are quantitatively obtained. After the blood pump generates the initial upstroke peak
ow, this setup is used to generate the systolic and diastolic phases of the pulse ow waves
and the ow pulsatility varies without changing the mean ow rate. The apparatus used for
cell studies is parallel plate ow chamber. The chamber is made of an acrylic top that is
placed over a slide or a co-culture setup with an attached silicone gasket. A schematic of the
culture chamber is shown in Fig. 5.1A. Here the ow region is 30 mm in width and 60 mm in
length, and the height of the ow channel above the slide is 0.54 mm. The culture chamber
is held to the slide by a vacuum channel sealed around the perimeter of the chamber. The
uid enters through an inlet port, goes through the uid region and expands into the inlet
reservoir.
5.2.2 Numerical Model
It is dicult and complex to measure the actual values of shear stress in this given the
small dimensions of the system which needs to measure the velocity within ow chamber
at appropriate locations. CFD with accurate initial, boundary conditions and properties
of ow and solid provides maps of uid ow at locations throughout the ow chamber to
obtain the shear stress. It is important to ensure that the computed level of shear the cells
are exposed to for a particular ow setting matches the actual shear stress. Therefore, CFD
results need to be compared to actual measurements for at least a sub-set of ow conditions.
CFD modeling was used as a design tool to provide maps of velocity, pressure and shear
stress at locations throughout the ow chamber resulting in a uniform test area. First a
three dimensional model was examined by Dr. Wei Tan's group. Due to the unique ow
distribution along the width of chamber, a two dimensional rigid model is developed to
simplify the three dimensional rigid model to save computational time. The experimental
setup includes a soft collagen surface in order to include this in the computational model
a full 2D compliant model with uid structure interaction is developed based on the rigid
2D model. Figure 5.4 shows the schematic of compliant 2D model. The collagen compliant
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Figure 5.1: (A) The ow chamber design with an inlet and outlet reservoirs and a vacuum
channel (mm). (B) A schematic of the ow setup shows the circulation of uid starting from
and ending to the uid reservoir with a compliance adjustment chamber controlling the
pulsatility of the ow waves. (C) The three graphs show the inuence that the compliance
adjustment chamber has on the contour of the pulse ow wave.
matrix is represented by the solid portion of the model. The length of model is 50 mm and
the thicknesses of uid and collagen membrane are 0.5 mm.
Fluid Domain: The uid used in simulated ow culture chamber models was cell
media, which has properties similar to that of water at 37 C. Therefore, we use the properties
of water at 37 C in the model. The water in the chamber is modeled as an incompressible,
laminar, Newtonian uid with a viscosity 0.703 mPas and density 933 kg/m3. The stress
vector is continuous across the uid structure boundary, where the no-slip condition is applied
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Figure 5.2: The three inlet velocity time history proles.
to the uid velocity vector. The inlet ow rate is transient, with pulse shape obtained from
clinical measurements (Fig. 5.2). The outlet boundary condition of the ow domain is
specied as a resistance boundary condition as the same as previous model. The PVR for
the low, medium and high pulse cases are 1.06, 1.21 and 1.02 mm Hg/(L/min).
The Wormsley number is a dimensionless expression of the pulsatile ow frequency
in relation to viscous eects. For pulsatile ow condition, the velocity prole is aected
by frequency, which is related to the Womersley number that expresses pulse frequency in
relation to viscous eects.
 = h
q
!= (5.1)
here h is height of chamber 0.54 mm, ! is the angular frequency of the oscillations
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expressed as ! = 2=T ,  is the water density 933 kg/m3 and  is the viscosity of 0.703
mPas. The T is the period of pulse ow 1 s. After calculation, the Wormsley number is only
1.44 for this system. It means the frequency of pulsations is suciently low that a parabolic
velocity prole is developed during each cycle. Here we can consider the ow prole is nearly
parabolic, and numerical model and simulation are necessary.
Solid Domain: The compliant 2D model contains a solid domain, which represents
the collagen gel in the experimental setup. The solid wall is considered an incompressible
isotropic linear elastic model with density 3100 kg/m3 and Poison's ratio 0.4. The wall is
constrained while exterior boundary surface has zero displacement due to an attached glass
slide, and interior boundary surface is loaded with uid pressure/shear stress, respectively.
Solution Procedure: The two dimensional and three dimensional computational
models include the entrance to the chamber, a reservoir and the channel region. Based on the
assumption that the spatially non-uniform ows at the inlet and exit are approximately equal
in size, the culture chamber area was modeled up to the point of steady shear. This decreased
the computational time and memory requirements. For the 3D model was carried out by
Devon Scott, and here briey description is shown. A rectangular mesh was employed in the
computation domain with grid spacing of 13 mm which ensures robust spatial representation
of velocity values in the ow region (Fig. 5.3). The nal grid spacing was determined by a
grid convergence study that terminated upon nding changes of less than 1% in velocities
between renements at 5 selected locations in the model. The 2D and 3D geometries and
grid structures were both generated with CFD-GEOM (ESI Group, Paris, France). The
dimensions of inlet and outlet regions are shown in Fig. 5.5.
The CFD-ACE multiphysics package (CFD Research Corporation, CA, USA) is used to
perform mesh generation, develop the numerical model, and to solve the governing equations
for uid ow with the nite volume method and the equations of motion for the structure
with the nite element method. A rectangular mesh is generated and the total mesh number
is 3003 in uid domain and 606 in solid domain (Fig. 5.5). The time step is 5 ms. A total
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time of 3 seconds is calculated for all cases to insure that the simulations are convergent in
the transient inlet condition; the resistance boundary condition coupled with wall stiness
allows for uid storage, which can take several cardiac cycles to become periodic.
Figure 5.3: The computational grid for the 3D rigid ow chamber is rened until there is
less than a 1% dierence in the velocity values.
5 cm
1 cm 1 cm
1 cm
h = 0.54 mm
Flow Domain
Solid Domain
h
h
Figure 5.4: Schematic of the 2D compliant computational model, illustrating both the uid
and solid domain and the uid solid interaction.
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Figure 5.5: The computation grid for the 2D compliant model with uid-structure interac-
tion.
Experimentally measured inlet ow proles were used to as transient inlet boundary
condition for the computational models and the inlet velocity is constant spatially. Figure
5.2 shows the low, medium and high pulsatile ow waves used as inlet boundary condition.
These ow waveforms were taken from the ow meter at the exit of the compliance chamber,
thereby introducing the aect of changing upstream compliance into the system. Reynolds
number was calculated for all the ow conditions and the peak Re for each condition was
22.21, 24.2, 29.78, respectively. These conrm the ow in the chamber is laminar. Flow
data from the computational solution was analyzed at dierent longitudinal points along the
2D compliant chamber to examine the temporal variation. These points were taken from
the bottom layer of uid (layer that would directly aect the cells) at the inlet, middle and
outlet of the ow region. To understand spatial variation of ow velocity, velocity values
were obtained horizontally across the 3D chamber from one wall to the opposite wall, thus
yielding a velocity prole across the width of the chamber. This was repeatedly done at the
inlet, middle and outlet of the chamber. Spatial variation was also mapped through the ow
region depth, measuring at one time point from the bottom of the ow region up through the
top layer of uid. In order to nd the entrance length, velocity values were take at one time
point longitudinally from the exit of the reservoir or beginning of the test region until the
velocity variation was less then 1%. The shear stress was calculated from the uid velocity
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as shown in chapter 2. In the 2D model, we rened mesh to 8 to analyze the ow eect at
the inlet and outlet corners. Figures 5.6 and 5.8 show the velocity magnitude maps at the
inlet and outlet corners at the minimum ow rate with 1 and 8 meshes. Here the default
velocity legend and user specied velocity legend are used separately to clearly show the uid
velocity maps at the upper and lower corners respectively. Maximum velocities are 4.901
mm/s and 4.933 mm/s for 1 and 8 meshes and the dierence is less than 1%. Figures 5.7
and 5.9 show the velocity magnitude maps at the inlet and outlet corners at the maximum
ow rate with 1 and 8 meshes. The dierence of velocity magnitude between 1 and 8
meshes is also less than 1% at the maximum ow rate. From the velocity magnitude maps
we obtain that they are identical between rened and unrened meshes which clearly prove
that our mesh is good enough for numerical simulation.
5.2.3 Post Numerical Data Processing
The WSS is calculated and the derivation of WSS from velocity is performed by tting
the velocity data with a polynomial function as we did in previous chapters.
Calculation of the pulsatility index, evaluation of spectral content using a discrete fast
fourier transform, and calculation of the hemodynamic energy were taken to quantify the
pulsatile ow waveform or the level of ow pulsatility. The ow pulsatility index is usually
used in the evaluation of vascular stiening eects [126] and is dened as:
PI = (umax   umin)=umean (5.2)
where umax is the peak systolic velocity, umin is the minimum forward diastolic velocity
and umean is the average velocity.
Spectral analysis was performed to examine dierences in frequency content among
the three ow waveforms used in this study. MATLAB software (Matworks, Natick, MA) is
used to calculate the modulus based on harmonics and WSS. The modulus calculation can
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Figure 5.6: Velocity magnitude map at the inlet and outlet corners at the minimum ow
rate with 1 and 8 meshes(default velocity legend).
be refereed to previous work. The analysis focuses mainly on the rst harmonic because it
is the main determinate of pulsatile ow. In order to compare the energy dissipated by each
ow waveform, the energy equivalent pressure (EEP) was calculated [127]. This was given
by the formula
EEP =
Z
PQdt=
Z
Qdt (5.3)
where Q is the pump ow rate, and P is the ow pressure. Previous study shows the
pulsatility index is often used in the evaluation of vascular diseases [128].
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Figure 5.7: Velocity magnitude map at the inlet and outlet corners at the maximum ow
rate with 1 and 8 meshes(default velocity legend).
5.2.4 Quantication of Flow Waveform
Quantication of ow waveform was studied by Dr. Wei Tan' group and briey de-
scribed here. The pulsatility index for the high, medium, and low pulse ow waves are 2.67,
1.68, and 0.78, respectively. The moduli for the three ow waves studied are shown in Fig.
5.10. The high pulse ow wave has the highest modulus, while the medium ow rate is in
mid level and the low pulse ow rate has the lowest modulus. The modulus is not aected
by the applied frequency as we have previously shown a similar result with pulsatile ows at
2 Hz [76]. In addition to pulsatile velocity waves, pressure waves are needed for calculation
of pulsatile hemodynamic energy, shown in Fig. 5.11. The pressure and ow waveforms
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Figure 5.8: Velocity magnitude map at the inlet and outlet corners at the minimum ow
rate with 1 and 8 meshes(dened velocity legend 0-0.0001 m/s).
from the experimental setup are have similar wave contours, but there is a phase dierence
between them due to pressure gradient present in the ow area. The EEP for the high,
medium and low pulse ow waves is 340, 240, and 83 mm Hg, respectively. These show
that when the mean ow rate and the frequency are constant, a ow condition with a higher
pulsatility index and higher rst and second harmonic modulus have a greater energy level
associated with the waveform. The quantitative descriptions of the ow waveforms employed
in this study demonstrates that these waveforms represent ow conditions at varied pulsatil-
ity and energy level due to varied upstream compliance. Thus, the results demonstrated
with these waveforms can be applied to a wide range of ow conditions that are correlated
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Figure 5.9: Velocity magnitude map at the inlet and outlet corners at the maximum ow
rate with 1 and 8 meshes(dened velocity legend 0-0.008 m/s).
with upstream stiening eects.
5.3 Results
5.3.1 Comparison of Velocity Proles in 2D and 3D Computational Flow
Chambers
The centerline velocities at the chamber middle point are compared between simplied
2D and 3D models in Fig. 5.12. The velocity proles of the 2D and 3D rigid models are
identical, which indicates that the 2D model is an acceptable simplied representation of the
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Figure 5.10: Spectral analysis of the high, medium, and low pulse waveforms with the
harmonic modulus.
3D model. The compliant 2D model is also shown in Fig. 5.4, as can be seen in this graph
the compliant structure dampens the ow pulsations. Therefore, it is reasonable to simplify
the model to the 2D compliant model in order to understand the temporal ow propagation
with a more realistic compliant surface. However, the 3D model will still provide the spatial
characterization of ow across the width of the chamber.
5.3.2 Characterization of Temporal Variation of Pulse Flow Waves
Temporal variations in ow waveforms across the chamber were also examined here.
The temporal variation was examined using the 2D compliant model; this model results
in more accurate ow proles by the inclusion of the complaint collagen matrix. The ow
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Figure 5.11: Flow waves and Pressure waves for the high, medium, and low pulsations.
waveform was obtained from the computational model at dierent longitudinal points along
the chamber, near the inlet, in the middle and near the outlet of the chamber for each
of the three selected ow conditions to examine the propagation of the ow prole along
the chamber. The graphs in Fig. 5.13 show that ow waveform slightly varies at points
throughout the uniform region, evident in the fact that all of there is a decrease in ow time-
histories along the length of the channel as the wave is propagated. This suggests that as
the ow wave travels throughout the channel some energy is dissipated due to the compliant
collagen matrix, which impedes the wave propagation through the chamber; this is similar
to the experimental setup. The ow rate waveforms at the inlet, middle and outlet have
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Figure 5.12: Graph of the 3D rigid model vs. the 2-rigid and 2D compliant model. Showing
the 3D and 2D rigid models result in the same for waves for low, medium and high pulse.
phase shaft between them, but the phase shaft is very small. Such as, for the high pulse ow,
the time dierence between inlet peak ow rate and outlet peak ow rate is only 5ms. The
reason is that at the outside of collagen compliant matrix (compliant wall), a glass is put to
restrict the motion of the wall (zero displacement on wall outer boundary), which restricts
the deformation of the compliant wall. The displacement of compliant wall/uid interface is
small. As a result the storage capacity of the chamber is very small, which makes the phase
shaft between inlet and outlet ow small. The decrease of the ow pulsatility during ow
propagation in chamber is aected by the wall shear, which relates to the elastic modulus
and Poisson ratio.
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Whereas in the rigid 2D and 3D models there is instantaneous propagation of the ow
wave is due to the lack of compliance in the rigid model and the model's rigidity; this is not
the case in the experimental setup. Therefore, the compliant 2D model gives a more accurate
measurement of the ow behavior. As a result of no ow dampening at the inlet computed
inlet ow prole is identical to the rigid ow proles, whereas the compliant surface dampens
the ow as the wave propagates. Additionally, the shear stress in the chamber is calculated
based on the spatial derivative of velocity. Table 5.1 displays the peak and mean shear
stresses averages for the three ow waves.
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Figure 5.13: Temporal velocity time-history waves for the 3 ow proles (shown in Fig. 5.4)
tested in three regions of the chamber, near the inlet, in the middle of the channel, and near
the exit of the model.
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Table 5.1: Mean and peak shear stresses for the low, medium and high pulse ow waves.
Velocity wave Mean shear (Dyn/cm2) Peak shear (Dyn/cm2)
Low 1.13 1.35
Medium 1.15 1.77
High 1.05 2.46
5.3.3 Experimental Comparison with Computational Model Results
A comparison of the velocity proles from experimental measurements with those from
the 2-D compliant computational model provides a validation of the test section function.
The comparisons between computational and experimental outlet velocities for the high,
medium and low pulse ow waves are shown in Fig. 5.14. The 2D compliant model simulates
similar ow proles with the experimental outlet ow. The largest percent dierence between
the computational and experimental outlet velocities is found to be <10%, this occurs in
the high ow wave, the other ow waves have a small amount of discrepancy, <5%, with
computational simulations. Due to some limitations in the experimental setup for the high
ow wave only, we developed a corrected high ow wave to compare the outlet ow rate
with the experimental high pulse wave. Despite the small dierences, we nd this to be an
acceptable error. Therefore, the result conrms that the velocities along the experimental
chamber are uniform and the calculated shear stresses are similar to the actual shear stresses.
5.4 Discussion
This study developed a ow co-culture system by Dr. Wei Tan's group, in which
arterial like pulse ow waves with varied levels of ow pulsatility in correlation with up-
stream compliance are generated and imposed onto downstream vascular cell co-cultures
in a ow chamber. The study also developed a structurally based model which accounts
for the temporal and spatial propagation of the pulse ow waves in the ow chamber and
thus guides the design of the chamber. Combining CFD design of the culture region with
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Figure 5.14: The ow waves of low, medium and high pulses for the computation and
experiment at outlet boundary.
experimental approaches including ow measurements and biological analyses, we identied
a spatiotemporally uniform ow region in the chamber where cells are exposed to the same
pulse ow waves and thus can be collected to accurately determine the ow pulsatility- or
waveform- specic eects on cells. Using this system, we also demonstrated the dierence
between EC-SMC co-culture in response to steady ow and pulse ow conditions. Addition-
ally, the ow culture chamber provides a large area of uniform ow, which is important for
cell signaling studies that involve a large number (>105) of cells. The new system will be
useful to easily investigate the relationship between arterial stiening, ow pulsatility and
vascular remodeling. Results from this study can be applied to a range of chamber designs
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and ow conditions yielding a similar large uniform ow region. An alternative method to
produce a larger uniform region is to widen the channel or to reduce the channel height,
both of which can increase the Womersley number yielding similar results as increasing the
frequency, according to the Womersley number denition. In the present study, a frequency
of 1 Hz yields a Womersley number of 1.44. At this Womersley number a at, blunt ow
prole pervades in the chamber, while a parabolic velocity prole is present in the chamber
depth direction. This is in good agreement with previous studies by Chung et.al. [129] and
Nauman et. al. [130]. There are several unique aspects in this study. First, this study pro-
vided description of spatiotemporal variations of pulse ow waves in the ow chamber. The
initial 3D rigid model was able to compute the ow prole experienced by the cells across
the chamber width. While the 2D model included a compliant collagen matrix, therefore,
an accurate temporal ow wave for cells on a non-rigid surface was computed. Second, this
study compared computational results with both experimental ow measurements and cell
analyses including gene and protein analyses. As demonstrated by the comparison between
the computational and experimental outlet ow waves the addition of the compliant surface
computes ow proles that are similar to the experimental setup. Lastly, the unique ow
system developed for this study conveniently and easily generates a series of pulse ow waves
that simulate diastolic and systolic phases of arterial ow. More importantly, changes in di-
astolic and systolic phases of these pulsatile ow waveforms correlate with changes in ow
pulsatility and upstream compliance while maintaining the same mean ow rate. This allows
separation of ow pulsatility eects (i.e. temporal variation of ow) and ow magnitude ef-
fects. This separation represents a major departure from most previous ow mechanobiology
studies which often employ reduced and oscillatory ow conditions [131, 132, 100, 125]. As it
has become increasingly known that the analysis of pulse wave contour in relation to arterial
stiness has potential to determine risk for cardiovascular diseases [97], pulse ow waveform
or ow pulsatility was quantitatively described with several methods in the present study.
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5.5 Limitations
Several limitations need to be acknowledged. The computational model is a simplistic
representation of the experimental ow chamber; as a result of this simplistic approach the
computational model will not identically replicate the experimental ow chamber. This
explains some of the error that occurs when the computational and experimental ow waves
were compared. CFD was used solely as a design tool to dene a uniform region of pulsatile
ow. The uid-structure interactions and aect of wave propagation phenomena add a more
realistic approach to the computational model. Therefore, the ow wave and shear stress is
not identical throughout the chamber, however we found that this does not drastically eect
cell expression. We are not able to model all aspects of the experimental setup so there are
be dierences when the computational and experimental results are compared. Therefore,
the computation does not provide the exact results found in the experimental setup (<10%
error), but it is a simple way to discover a uniform ow area and a close estimate of the
velocities and shear stresses that the cells will experience.
Chapter 6
Conclusion
Numerical simulations of blood ow in the pulmonary arteries in children and new-
born calves were carried out and results were discussed and analyzed. The eect of vascular
stiness on pulmonary ow in progressing PAH is examined using a patient-specic and
patient-validated 2D numerical model. Comparison of 21 model runs to their correspond-
ing clinical data show good agreement between model predictions of impedance and mean
PA pressures and clinical measurements, thereby validating the model. PAH worsening was
modeled using data from three PAH outcomes groups; these show not only the expected
increase in mean PA pressures, but an increase in pressure pulsatility as well. Interestingly,
chronically increasing PA pressures decreased WSS, indicating the impact of increased PA
areas on WSS was greater than the impact of increased PVS. For a patient having mod-
erate PAH with elastin-based upstream vascular remodeling, moving from elastin-dominant
upstream vessel behavior to collagen-dominant behavior caused substantial increases in pres-
sure, pressure pulsatility and WSS pulsatility. For the same patient, reducing PVR through
a simulated vasodilator to a value equivalent to mild PAH did not decrease pressure pulsatil-
ity and in fact increased WSS pulsatility dramatically. Overall, these results suggest a close
association between PVS and hemodynamics and those treatments should target decreasing
or reversing upstream vascular remodeling in addition to decreasing mean pressures.
Secondary based on the similar model, the eect of vascular stiness on pulmonary ow
in simulated normotensive and hypertensive states were examined in the simple 2D numerical
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model for children. Results show that higher total afterload was caused by higher stiness in
cardiac circulation. Afterload in the normal pulmonary circulation is primarily dependent on
resistance; however, in hypertension strain-stiening of the vessels, accompanied by vascular
remodeling, stien the proximal vessels. We nd three primary impacts of this stiening: 1)
reduced diastolic runo, which in of itself yields less ecient ow; 2) changes in the shear-
stress prole, which could have implications on cellular signaling; and 3) increases in afterload
independent of resistance, which are currently ignored in clinical diagnosis. Based on the
parameters from the measured clinical data, which include PVR, PVS and inlet ow rate
proles, we can use this 2D model to predict the unmeasured properties of pulmonary artery
in children both for normotensive and hypertensive states. Then the changes of clinically
unmeasured properties of the pulmonary artery in children can be tracked which are used
to guide the clinical studies. Further study will examine these changes in three-dimensional,
patient specic models of the pulmonary vasculature.
Then the eect of PVR and PVS (elastic modulus and thickness) on pulmonary hemo-
dynamics in PAH progression and treatment were examined in a 2D numerical model using
specied data from calves in control and hypertensive conditions for validation. As the model
progresses from control state to hypertensive state, PVR, elastic modulus and thickness af-
fect the pulmonary ow respectively and quantitatively. The combined changes increase
the mean and pulsatile component of hemodynamics while decrease WSS which supports
the idea of distal WSS derangement in the PAH condition. Through studying the hemody-
namics and afterload in theoretical treatment of proximal vascular stiness by reversing its
change during PAH progression, besides the vasodilator treatment on PVR, future treatment
of PAH should be addressed more on decreasing or reversing proximal vascular remodeling.
Future work will address model simplicity with the use of a hyperelastic material model and
a more branched distal geometry.
Finally a new ow system had been developed and characterized that exposes co-
cultured cells to arterial-like pulse ow waves. A computational uid dynamics model as
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well as experimental measurement designed a uniform ow region for cell mechanobiology
studies. This ow system provides the ability to study the eects up stream stiness on
pulsatile ow and WSS. The demonstrated system provides a valuable tool to study vascular
cell remodeling in relation to mechanical environment involving changes in vascular stiness
or ow pulsatility.
Chapter 7
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